peng321的个人主页 - 老虎社区

peng321

暂无个人介绍

IP属地：未知

300关注

96粉丝

0主题

0勋章

2021-08-18

Tepper sell mostly FAANG counter and adding Uber ..... holding cash or expecting buy in dip!

抱歉，原内容已删除

2021-08-04

Vaccine follow by booster.... then booster combine w flu med ...how many vaccine a human need!

3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>

2021-09-10

10 to 15% good for buy the dip

抱歉，原内容已删除

2021-08-09

Too big to move exponentially...this will be long term investment

抱歉，原内容已删除

2021-07-29

With herd immunity and movement allowed, screen time will be reduce..everyone is looking forward to step out

抱歉，原内容已删除

2021-07-13

So volatile, bad news and good news one after another

抱歉，原内容已删除

2021-07-12

looking forward

抱歉，原内容已删除

2021-08-23

BRK & SE .... the least also 10% return pa .... long term holding ..[美金] [美金]

抱歉，原内容已删除

2021-07-13

Good

抱歉，原内容已删除

2021-12-21

Strongly agree

Apple Stock: If You're Buying the Dip, Here's What You Need to Know<blockquote>苹果股票：如果您要逢低买入，以下是您需要了解的内容</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4087387556186030","uuid":"4087387556186030","gmtCreate":1624368214539,"gmtModify":1624368214539,"name":"peng321","pinyin":"peng321","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":96,"headSize":300,"tweetSize":25,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.15","exceedPercentage":"60.72%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":693715823,"gmtCreate":1640079044082,"gmtModify":1640079045141,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Strongly agree","listText":"Strongly agree","text":"Strongly agree","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693715823","repostId":"1112391676","repostType":4,"repost":{"id":"1112391676","kind":"news","pubTimestamp":1640056217,"share":"https://www.laohunote.com/m/news/1112391676?lang=zh_CN&edition=full","pubTime":"2021-12-21 11:10","market":"us","language":"en","title":"Apple Stock: If You're Buying the Dip, Here's What You Need to Know<blockquote>苹果股票：如果您要逢低买入，以下是您需要了解的内容</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1112391676","media":"TheStreet","summary":"Bargain hunters may start to consider buying Apple stock on the dip, following the December selloff. Here is what they should know first.Apple stock remains in a funk. Only one week to the dayafter I tossed around the ideaof trimming the position, shares of the Cupertino company dipped 7% from the $180 peak against the Nasdaq’s 4% decline, nearly entering correction territory.A few brave investors and traders must be taking this opportunity to start buying the dip. The Apple Maven highlights thr","content":"<p>Bargain hunters may start to consider buying Apple stock on the dip, following the December selloff. Here is what they should know first.</p><p><blockquote>继 12 月抛售之后，逢低买入苹果股票可能会开始考虑逢低买入。以下是他们首先应该知道的。</blockquote></p><p> Apple stock&nbsp;remains in a funk. Only one week to the dayafter I tossed around the ideaof trimming the position, shares of the Cupertino company dipped 7% from the $180 peak against the Nasdaq’s 4% decline, nearly entering correction territory.</p><p><blockquote>苹果股票仍然恐慌。在我抛出削减头寸的想法仅仅一周后，这家库比蒂诺公司的股价从 180 美元的峰值下跌了 7%，而纳斯达克则下跌了 4%，几乎进入了回调区。</blockquote></p><p> A few brave investors and traders must be taking this opportunity to start buying the dip. The Apple Maven highlights three facts that these bargain hunters should keep in mind.</p><p><blockquote>一些勇敢的投资者和交易者一定会抓住这个机会开始逢低买入。这位苹果专家强调了这些抄底者应该记住的三个事实。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a182a349bbd4ca16a13dace221ec341e\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple store in China.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：苹果在华门店。</span></p></blockquote></p><p> <b>#1. Valuations are looking more attractive</b></p><p><blockquote><b>#1.估值看起来更具吸引力</b></blockquote></p><p> AAPL is far from being a dirt cheap stock. The price-to-earnings ratio today is still higher than it had been for at least the full decade prior to the start of the pandemic (see chart below). However, with the recent decline in share price but still resilient business fundamentals, valuations are starting to look more compelling.</p><p><blockquote>AAPL 远非一只非常便宜的股票。如今的市盈率仍然高于疫情爆发前至少整整十年的水平（见下图）。然而，随着最近股价下跌但业务基本面仍然有弹性，估值开始看起来更具吸引力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/75ae50cce66d14520a3db0ce721b79a3\" tg-width=\"827\" tg-height=\"389\" width=\"100%\" height=\"auto\"><span>Figure 2: AAPL's historical price-to-earnings ratio.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图 2：AAPL 的历史市盈率。</span></p></blockquote></p><p> The last read on the graph above shows a P/E of 29.0 times as of November 30. As of last check, on December 20, the fiscal 2022 multiple had dropped to 27.5 times. These are roughly the same levels of June 2020, after which Apple stock moved 85% higher in a year and a half.</p><p><blockquote>上图的最后一次读数显示，截至 11 月 30 日，市盈率为 29.0 倍。截至 12 月 20 日的最后一次检查，2022 财年倍数已降至 27.5 倍。这些水平与 2020 年 6 月大致相同，之后苹果股价在一年半内上涨了 85%。</blockquote></p><p> <b>#2. The deeper the hole, the higher the gains</b></p><p><blockquote><b>#2.洞越深，收益越高</b></blockquote></p><p> “Buy low, sell high”. The mantra may seem overly simplistic, but the strategy has worked wonders in the case of AAPL.</p><p><blockquote>“低买高卖”。这个口头禅可能看起来过于简单，但这个策略在苹果公司的案例中创造了奇迹。</blockquote></p><p> We have often mentioned here, on the Apple Maven channel, that shares of the Cupertino company&nbsp;do best when bought after a selloff. Historically, the one-year gains have been 22% when the stock is bought near a peak, but nearly 40% when bought after a 15% drawdown.</p><p><blockquote>我们经常在苹果 Maven 频道上提到，库比蒂诺公司的股票在抛售后买入时表现最好。从历史上看，当股票在峰值附近买入时，一年涨幅为 22%，但在下跌 15% 后买入时，一年涨幅接近 40%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9439be7d48cbf04254a822d9d57576f3\" tg-width=\"601\" tg-height=\"361\" width=\"100%\" height=\"auto\"><span>Figure 3: Average one-year return on AAPL, by strategy.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图 3：按策略划分的 AAPL 平均一年回报率。</span></p></blockquote></p><p> Could this time be different for dip buyers? I think not. To be clear, I do not believe that every stock is worth owning on weakness, as “40% of all stocks have&nbsp;suffered&nbsp;a permanent 70%-plus decline from their peak value”.</p><p><blockquote>对于逢低买家来说，这次会有所不同吗？我不这么认为。需要明确的是，我并不认为每只股票都值得在疲软时持有，因为 “40% 的股票从峰值永久性下跌了 70% 以上”。</blockquote></p><p> But in the case of Apple, it is highly likely that share price will eventually head higher again, shaking off short-term bearishness and chasing the strong business fundamentals. Having the patience to wait for the next rally is crucial.</p><p><blockquote>但就苹果而言，股价最终极有可能再次走高，摆脱短期看跌情绪，追逐强劲的商业基本面。耐心等待下一次反弹至关重要。</blockquote></p><p> <b>#3. Don’t underestimate volatility</b></p><p><blockquote><b>#3.不要低估波动性</b></blockquote></p><p> All the above sounds bullish at first glance, and an incentive to buy Apple at the current share price of around $168. But if doing so, I urge traders and investors to pay attention to volatility.</p><p><blockquote>乍一看，以上所有情况听起来都很乐观，并且是以目前 168 美元左右的股价购买苹果的动力。但如果这样做，我敦促交易者和投资者关注波动性。</blockquote></p><p> The emotional and psychological aspects of investing can be as important as the quantitative considerations, in my view. Those who buy dips must be willing to endure higher volatility, which has increased sharply for AAPL in the past few weeks — see below.</p><p><blockquote>在我看来，投资的情感和心理方面与数量方面的考虑一样重要。那些逢低买入的人必须愿意忍受更高的波动性，而过去几周 AAPL 的波动性急剧增加——见下文。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eace3c9293acb54a4dc217debd6a44be\" tg-width=\"618\" tg-height=\"370\" width=\"100%\" height=\"auto\"><span>Figure 4: Annual volatility in AAPL, 1-month rolling.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图 4：AAPL 的年度波动性，1 个月滚动。</span></p></blockquote></p><p> Because Apple stock price is likely to ricochet in the short term, some might be tempted to sell their shares prematurely, should they drop well below current levels. If buying AAPL, be sure to have a clear exit strategy to avoid falling victim to spur-of-the-moment decisions.</p><p><blockquote>由于苹果股价可能在短期内反弹，如果股价远低于当前水平，一些人可能会试图过早出售股票。如果购买 AAPL，请务必制定明确的退出策略，以避免成为一时冲动决定的受害者。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: If You're Buying the Dip, Here's What You Need to Know<blockquote>苹果股票：如果您要逢低买入，以下是您需要了解的内容</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: If You're Buying the Dip, Here's What You Need to Know<blockquote>苹果股票：如果您要逢低买入，以下是您需要了解的内容</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-12-21 11:10</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Bargain hunters may start to consider buying Apple stock on the dip, following the December selloff. Here is what they should know first.</p><p><blockquote>继 12 月抛售之后，逢低买入苹果股票可能会开始考虑逢低买入。以下是他们首先应该知道的。</blockquote></p><p> Apple stock&nbsp;remains in a funk. Only one week to the dayafter I tossed around the ideaof trimming the position, shares of the Cupertino company dipped 7% from the $180 peak against the Nasdaq’s 4% decline, nearly entering correction territory.</p><p><blockquote>苹果股票仍然恐慌。在我抛出削减头寸的想法仅仅一周后，这家库比蒂诺公司的股价从 180 美元的峰值下跌了 7%，而纳斯达克则下跌了 4%，几乎进入了回调区。</blockquote></p><p> A few brave investors and traders must be taking this opportunity to start buying the dip. The Apple Maven highlights three facts that these bargain hunters should keep in mind.</p><p><blockquote>一些勇敢的投资者和交易者一定会抓住这个机会开始逢低买入。这位苹果专家强调了这些抄底者应该记住的三个事实。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a182a349bbd4ca16a13dace221ec341e\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple store in China.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：苹果在华门店。</span></p></blockquote></p><p> <b>#1. Valuations are looking more attractive</b></p><p><blockquote><b>#1.估值看起来更具吸引力</b></blockquote></p><p> AAPL is far from being a dirt cheap stock. The price-to-earnings ratio today is still higher than it had been for at least the full decade prior to the start of the pandemic (see chart below). However, with the recent decline in share price but still resilient business fundamentals, valuations are starting to look more compelling.</p><p><blockquote>AAPL 远非一只非常便宜的股票。如今的市盈率仍然高于疫情爆发前至少整整十年的水平（见下图）。然而，随着最近股价下跌但业务基本面仍然有弹性，估值开始看起来更具吸引力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/75ae50cce66d14520a3db0ce721b79a3\" tg-width=\"827\" tg-height=\"389\" width=\"100%\" height=\"auto\"><span>Figure 2: AAPL's historical price-to-earnings ratio.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图 2：AAPL 的历史市盈率。</span></p></blockquote></p><p> The last read on the graph above shows a P/E of 29.0 times as of November 30. As of last check, on December 20, the fiscal 2022 multiple had dropped to 27.5 times. These are roughly the same levels of June 2020, after which Apple stock moved 85% higher in a year and a half.</p><p><blockquote>上图的最后一次读数显示，截至 11 月 30 日，市盈率为 29.0 倍。截至 12 月 20 日的最后一次检查，2022 财年倍数已降至 27.5 倍。这些水平与 2020 年 6 月大致相同，之后苹果股价在一年半内上涨了 85%。</blockquote></p><p> <b>#2. The deeper the hole, the higher the gains</b></p><p><blockquote><b>#2.洞越深，收益越高</b></blockquote></p><p> “Buy low, sell high”. The mantra may seem overly simplistic, but the strategy has worked wonders in the case of AAPL.</p><p><blockquote>“低买高卖”。这个口头禅可能看起来过于简单，但这个策略在苹果公司的案例中创造了奇迹。</blockquote></p><p> We have often mentioned here, on the Apple Maven channel, that shares of the Cupertino company&nbsp;do best when bought after a selloff. Historically, the one-year gains have been 22% when the stock is bought near a peak, but nearly 40% when bought after a 15% drawdown.</p><p><blockquote>我们经常在苹果 Maven 频道上提到，库比蒂诺公司的股票在抛售后买入时表现最好。从历史上看，当股票在峰值附近买入时，一年涨幅为 22%，但在下跌 15% 后买入时，一年涨幅接近 40%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9439be7d48cbf04254a822d9d57576f3\" tg-width=\"601\" tg-height=\"361\" width=\"100%\" height=\"auto\"><span>Figure 3: Average one-year return on AAPL, by strategy.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图 3：按策略划分的 AAPL 平均一年回报率。</span></p></blockquote></p><p> Could this time be different for dip buyers? I think not. To be clear, I do not believe that every stock is worth owning on weakness, as “40% of all stocks have&nbsp;suffered&nbsp;a permanent 70%-plus decline from their peak value”.</p><p><blockquote>对于逢低买家来说，这次会有所不同吗？我不这么认为。需要明确的是，我并不认为每只股票都值得在疲软时持有，因为 “40% 的股票从峰值永久性下跌了 70% 以上”。</blockquote></p><p> But in the case of Apple, it is highly likely that share price will eventually head higher again, shaking off short-term bearishness and chasing the strong business fundamentals. Having the patience to wait for the next rally is crucial.</p><p><blockquote>但就苹果而言，股价最终极有可能再次走高，摆脱短期看跌情绪，追逐强劲的商业基本面。耐心等待下一次反弹至关重要。</blockquote></p><p> <b>#3. Don’t underestimate volatility</b></p><p><blockquote><b>#3.不要低估波动性</b></blockquote></p><p> All the above sounds bullish at first glance, and an incentive to buy Apple at the current share price of around $168. But if doing so, I urge traders and investors to pay attention to volatility.</p><p><blockquote>乍一看，以上所有情况听起来都很乐观，并且是以目前 168 美元左右的股价购买苹果的动力。但如果这样做，我敦促交易者和投资者关注波动性。</blockquote></p><p> The emotional and psychological aspects of investing can be as important as the quantitative considerations, in my view. Those who buy dips must be willing to endure higher volatility, which has increased sharply for AAPL in the past few weeks — see below.</p><p><blockquote>在我看来，投资的情感和心理方面与数量方面的考虑一样重要。那些逢低买入的人必须愿意忍受更高的波动性，而过去几周 AAPL 的波动性急剧增加——见下文。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eace3c9293acb54a4dc217debd6a44be\" tg-width=\"618\" tg-height=\"370\" width=\"100%\" height=\"auto\"><span>Figure 4: Annual volatility in AAPL, 1-month rolling.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图 4：AAPL 的年度波动性，1 个月滚动。</span></p></blockquote></p><p> Because Apple stock price is likely to ricochet in the short term, some might be tempted to sell their shares prematurely, should they drop well below current levels. If buying AAPL, be sure to have a clear exit strategy to avoid falling victim to spur-of-the-moment decisions.</p><p><blockquote>由于苹果股价可能在短期内反弹，如果股价远低于当前水平，一些人可能会试图过早出售股票。如果购买 AAPL，请务必制定明确的退出策略，以避免成为一时冲动决定的受害者。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/apple/stock/apple-stock-3-key-facts-dip-buyers-must-know\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/stock/apple-stock-3-key-facts-dip-buyers-must-know","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112391676","content_text":"Bargain hunters may start to consider buying Apple stock on the dip, following the December selloff. Here is what they should know first.\nApple stock remains in a funk. Only one week to the dayafter I tossed around the ideaof trimming the position, shares of the Cupertino company dipped 7% from the $180 peak against the Nasdaq’s 4% decline, nearly entering correction territory.\nA few brave investors and traders must be taking this opportunity to start buying the dip. The Apple Maven highlights three facts that these bargain hunters should keep in mind.\nFigure 1: Apple store in China.\n#1. Valuations are looking more attractive\nAAPL is far from being a dirt cheap stock. The price-to-earnings ratio today is still higher than it had been for at least the full decade prior to the start of the pandemic (see chart below). However, with the recent decline in share price but still resilient business fundamentals, valuations are starting to look more compelling.\nFigure 2: AAPL's historical price-to-earnings ratio.\nThe last read on the graph above shows a P/E of 29.0 times as of November 30. As of last check, on December 20, the fiscal 2022 multiple had dropped to 27.5 times. These are roughly the same levels of June 2020, after which Apple stock moved 85% higher in a year and a half.\n#2. The deeper the hole, the higher the gains\n“Buy low, sell high”. The mantra may seem overly simplistic, but the strategy has worked wonders in the case of AAPL.\nWe have often mentioned here, on the Apple Maven channel, that shares of the Cupertino company do best when bought after a selloff. Historically, the one-year gains have been 22% when the stock is bought near a peak, but nearly 40% when bought after a 15% drawdown.\nFigure 3: Average one-year return on AAPL, by strategy.\nCould this time be different for dip buyers? I think not. To be clear, I do not believe that every stock is worth owning on weakness, as “40% of all stocks have suffered a permanent 70%-plus decline from their peak value”.\nBut in the case of Apple, it is highly likely that share price will eventually head higher again, shaking off short-term bearishness and chasing the strong business fundamentals. Having the patience to wait for the next rally is crucial.\n#3. Don’t underestimate volatility\nAll the above sounds bullish at first glance, and an incentive to buy Apple at the current share price of around $168. But if doing so, I urge traders and investors to pay attention to volatility.\nThe emotional and psychological aspects of investing can be as important as the quantitative considerations, in my view. Those who buy dips must be willing to endure higher volatility, which has increased sharply for AAPL in the past few weeks — see below.\nFigure 4: Annual volatility in AAPL, 1-month rolling.\nBecause Apple stock price is likely to ricochet in the short term, some might be tempted to sell their shares prematurely, should they drop well below current levels. If buying AAPL, be sure to have a clear exit strategy to avoid falling victim to spur-of-the-moment decisions.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":3622,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":855916155,"gmtCreate":1635323901479,"gmtModify":1635324029476,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Holding BRK.B, hassle free","listText":"Holding BRK.B, hassle free","text":"Holding BRK.B, hassle free","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855916155","repostId":"2178408679","repostType":4,"isVote":1,"tweetType":1,"viewCount":4935,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825816809,"gmtCreate":1634216569931,"gmtModify":1634216607695,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"SBUX one month Call looks cheap .... if earning can pump up the volatility,&nbsp; upside potential looks bright&nbsp;","listText":"SBUX one month Call looks cheap .... if earning can pump up the volatility,&nbsp; upside potential looks bright&nbsp;","text":"SBUX one month Call looks cheap .... if earning can pump up the volatility, upside potential looks bright","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825816809","repostId":"1161146997","repostType":4,"repost":{"id":"1161146997","kind":"news","pubTimestamp":1634201365,"share":"https://www.laohunote.com/m/news/1161146997?lang=zh_CN&edition=full","pubTime":"2021-10-14 16:49","market":"us","language":"en","title":"How Options Investors Should Play This Earnings Season<blockquote>期权投资者应如何应对这个财报季</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161146997","media":"Barrons","summary":"At the start of the third-quarter earnings season, let it be said that investors are nervous, analys","content":"<p>At the start of the third-quarter earnings season, let it be said that investors are nervous, analysts are generally worried about earnings growth, and the options market is a cauldron of coiled anxiety.</p><p><blockquote>在第三季度财报季开始之际，可以说投资者很紧张，分析师普遍担心盈利增长，期权市场是一个盘绕焦虑的大熔炉。</blockquote></p><p> The cause for this sour sentiment? Expectations that the Federal Reserve may soon raise interest rates, for a variety of reasons.</p><p><blockquote>这种不愉快情绪的原因？预期美联储可能很快加息，原因多种多样。</blockquote></p><p> The economy is beset by inflationary pressures. Supply chains are struggling to keep pace with consumer and corporate demand for everything from semiconductors to toilet paper. Economic growth, which ultimately drives corporate earnings, appears to be slowing, and that generally portends poorly for stock prices. The drama in Washington over raising the debt ceiling, and dueling legislative agendas, adds a circus-like air to the market.</p><p><blockquote>经济受到通货膨胀压力的困扰。供应链正在努力跟上消费者和企业对从半导体到卫生纸等各种产品的需求。最终推动企业盈利的经济增长似乎正在放缓，这通常对股价不利。华盛顿关于提高债务上限的戏剧性事件，以及立法议程的决斗，给市场增添了马戏团般的气氛。</blockquote></p><p> What is less discussed is that the rules of the game are changing. When the Fed finally raises interest rates, most investors will have to learn some new tricks.</p><p><blockquote>较少讨论的是游戏规则正在改变。当美联储最终加息时，大多数投资者将不得不学习一些新花样。</blockquote></p><p> After 20 years of easy-money policies, investors have come to rely on the mighty “Fed put”—the belief that the Fed will do whatever it takes to keep the stock market from falling too far. Now, it seems the Fed put&nbsp;might expire after this earnings season, and making money in the stock and options markets may no longer be so easy.</p><p><blockquote>经过 20 年的宽松货币政策，投资者开始依赖强大的 “美联储看跌期权 ”--即相信美联储会不惜一切代价防止股市下跌过多。现在，美联储看跌期权似乎可能会在本财报季后到期，在股票和期权市场赚钱可能不再那么容易。</blockquote></p><p> The good news? There are ways to monetize these unusual conditions during an event-heavy calendar.</p><p><blockquote>好消息？在事件密集的日历中，有一些方法可以将这些不寻常的情况货币化。</blockquote></p><p> There are many crosscurrents moving above and below the market’s surface. The&nbsp;S&amp;P 500 index&nbsp;is dancing around historic highs. Yet earnings estimates for the third quarter show little expectation that corporate earnings reports will prove to be much of anything—and this could create some opportunities for aggressive investors.</p><p><blockquote>市场表面之上和之下都有许多横流。标普500指数正在历史高位徘徊。然而，对第三季度的盈利预测显示，人们对企业盈利报告将证明是多么重要的期望——这可能会为激进的投资者创造一些机会。</blockquote></p><p> John Marshall,Goldman Sachs’ derivatives strategist, recently advised clients that analyst estimates for the third quarter have been revised upward by 12% over the past three months but still remain 2% below the second-quarter’s level (not including the financial sector).</p><p><blockquote>高盛（Goldman Sachs）衍生品策略师约翰-马歇尔（John Marshall）最近告诉客户，分析师对第三季度的预期在过去三个月中上调了12%，但仍比第二季度的水平低2%（不包括金融业）。</blockquote></p><p> Meanwhile, single-stock skew—the difference between bearish put-option and bullish call-option implied volatility—is at the highest level in over a year.</p><p><blockquote>与此同时，单股偏差（看跌看跌期权和看涨看涨期权期权隐含波动率之间的差异）处于一年多来的最高水平。</blockquote></p><p> The elevated skew suggests that investors have bought bearish puts to hedge earnings reports, thus creating conditions that could spark relief rallies in certain stocks on earnings day, and even in broad indexes, Marshall told clients. Investors are so pessimistic about corporate earnings—and have positioned that way in the options market—that any bit of good news could prompt strong moves in individual stocks.</p><p><blockquote>马歇尔告诉客户，这种偏差加大表明投资者购买了看跌看跌期权来对冲收益报告，从而创造了可能在收益日引发某些股票甚至广泛指数缓解反弹的条件。投资者对企业盈利非常悲观——并且在期权市场上也是如此——以至于任何一点好消息都可能引发个股的强劲波动。</blockquote></p><p> To trade these conditions, Marshall has assembled a list of stocks in which Goldman analysts are the most out of consensus with the Street view. On stocks that have the potential to beat earnings estimates, he has suggested that clients consider buying calls that expire in one month, with strike prices just above the current stock price.</p><p><blockquote>为了在这些条件下进行交易，马歇尔整理了一份高盛分析师与街头观点最不一致的股票清单。对于有可能超出盈利预期的股票，他建议客户考虑购买一个月后到期的评级，执行价格略高于当前股价。</blockquote></p><p> Goldman’s trading menu for stocks with potential upside to earnings estimates includes&nbsp;Starbucks&nbsp;(ticker: SBUX),Canadian Natural Resources&nbsp;(CNQ), YETI Holdings (YETI),Cenovus Energy&nbsp;(CVE), Carlyle Group (CG),Signature Bank&nbsp;(SBNY),Align Technology&nbsp;(ALGN),Maravai LifeSciences Holdings&nbsp;(MRVI),Fortune Brands Home &amp; Security&nbsp;(FBHS),Shoals Technologies Group&nbsp;(SHLS),CF Industries&nbsp;(CF),Okta&nbsp;(OKTA),Playtika Holding&nbsp;(PLTK), and&nbsp;Republic Services&nbsp;(RSG).</p><p><blockquote>高盛的交易菜单包括星巴克（股票代码：SBUX）、加拿大自然资源公司（CNQ）、YETI Holdings (YETI)、Cenovus Energy (CVE)、凯雷集团（CG）、Signature Bank (SBNY)、Align Technology (ALGN)、Maravai LifeSciences Holdings (MRVI)、Fortune Brands Home &amp; Security (FBHS)、Shoals Technologies Group (SHLS)、CF Industries (CF)、Okta (Okta)、Playtika Holding (PLTK) 和 Republic Services (RSG)。</blockquote></p><p> At a time when so many investors are confused about what to do, Goldman’s approach shows how a sophisticated strategist is thinking when change is in the air and investors are nervous about what comes next.</p><p><blockquote>在许多投资者对该做什么感到困惑的时候，高盛的做法显示了一位老练的策略师在变革即将来临、投资者对接下来会发生什么感到紧张时是如何思考的。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Options Investors Should Play This Earnings Season<blockquote>期权投资者应如何应对这个财报季</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Options Investors Should Play This Earnings Season<blockquote>期权投资者应如何应对这个财报季</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-10-14 16:49</span>\n</p>\n</h4>\n</header>\n<article>\n<p>At the start of the third-quarter earnings season, let it be said that investors are nervous, analysts are generally worried about earnings growth, and the options market is a cauldron of coiled anxiety.</p><p><blockquote>在第三季度财报季开始之际，可以说投资者很紧张，分析师普遍担心盈利增长，期权市场是一个盘绕焦虑的大熔炉。</blockquote></p><p> The cause for this sour sentiment? Expectations that the Federal Reserve may soon raise interest rates, for a variety of reasons.</p><p><blockquote>这种不愉快情绪的原因？预期美联储可能很快加息，原因多种多样。</blockquote></p><p> The economy is beset by inflationary pressures. Supply chains are struggling to keep pace with consumer and corporate demand for everything from semiconductors to toilet paper. Economic growth, which ultimately drives corporate earnings, appears to be slowing, and that generally portends poorly for stock prices. The drama in Washington over raising the debt ceiling, and dueling legislative agendas, adds a circus-like air to the market.</p><p><blockquote>经济受到通货膨胀压力的困扰。供应链正在努力跟上消费者和企业对从半导体到卫生纸等各种产品的需求。最终推动企业盈利的经济增长似乎正在放缓，这通常对股价不利。华盛顿关于提高债务上限的戏剧性事件，以及立法议程的决斗，给市场增添了马戏团般的气氛。</blockquote></p><p> What is less discussed is that the rules of the game are changing. When the Fed finally raises interest rates, most investors will have to learn some new tricks.</p><p><blockquote>较少讨论的是游戏规则正在改变。当美联储最终加息时，大多数投资者将不得不学习一些新花样。</blockquote></p><p> After 20 years of easy-money policies, investors have come to rely on the mighty “Fed put”—the belief that the Fed will do whatever it takes to keep the stock market from falling too far. Now, it seems the Fed put&nbsp;might expire after this earnings season, and making money in the stock and options markets may no longer be so easy.</p><p><blockquote>经过 20 年的宽松货币政策，投资者开始依赖强大的 “美联储看跌期权 ”--即相信美联储会不惜一切代价防止股市下跌过多。现在，美联储看跌期权似乎可能会在本财报季后到期，在股票和期权市场赚钱可能不再那么容易。</blockquote></p><p> The good news? There are ways to monetize these unusual conditions during an event-heavy calendar.</p><p><blockquote>好消息？在事件密集的日历中，有一些方法可以将这些不寻常的情况货币化。</blockquote></p><p> There are many crosscurrents moving above and below the market’s surface. The&nbsp;S&amp;P 500 index&nbsp;is dancing around historic highs. Yet earnings estimates for the third quarter show little expectation that corporate earnings reports will prove to be much of anything—and this could create some opportunities for aggressive investors.</p><p><blockquote>市场表面之上和之下都有许多横流。标普500指数正在历史高位徘徊。然而，对第三季度的盈利预测显示，人们对企业盈利报告将证明是多么重要的期望——这可能会为激进的投资者创造一些机会。</blockquote></p><p> John Marshall,Goldman Sachs’ derivatives strategist, recently advised clients that analyst estimates for the third quarter have been revised upward by 12% over the past three months but still remain 2% below the second-quarter’s level (not including the financial sector).</p><p><blockquote>高盛（Goldman Sachs）衍生品策略师约翰-马歇尔（John Marshall）最近告诉客户，分析师对第三季度的预期在过去三个月中上调了12%，但仍比第二季度的水平低2%（不包括金融业）。</blockquote></p><p> Meanwhile, single-stock skew—the difference between bearish put-option and bullish call-option implied volatility—is at the highest level in over a year.</p><p><blockquote>与此同时，单股偏差（看跌看跌期权和看涨看涨期权期权隐含波动率之间的差异）处于一年多来的最高水平。</blockquote></p><p> The elevated skew suggests that investors have bought bearish puts to hedge earnings reports, thus creating conditions that could spark relief rallies in certain stocks on earnings day, and even in broad indexes, Marshall told clients. Investors are so pessimistic about corporate earnings—and have positioned that way in the options market—that any bit of good news could prompt strong moves in individual stocks.</p><p><blockquote>马歇尔告诉客户，这种偏差加大表明投资者购买了看跌看跌期权来对冲收益报告，从而创造了可能在收益日引发某些股票甚至广泛指数缓解反弹的条件。投资者对企业盈利非常悲观——并且在期权市场上也是如此——以至于任何一点好消息都可能引发个股的强劲波动。</blockquote></p><p> To trade these conditions, Marshall has assembled a list of stocks in which Goldman analysts are the most out of consensus with the Street view. On stocks that have the potential to beat earnings estimates, he has suggested that clients consider buying calls that expire in one month, with strike prices just above the current stock price.</p><p><blockquote>为了在这些条件下进行交易，马歇尔整理了一份高盛分析师与街头观点最不一致的股票清单。对于有可能超出盈利预期的股票，他建议客户考虑购买一个月后到期的评级，执行价格略高于当前股价。</blockquote></p><p> Goldman’s trading menu for stocks with potential upside to earnings estimates includes&nbsp;Starbucks&nbsp;(ticker: SBUX),Canadian Natural Resources&nbsp;(CNQ), YETI Holdings (YETI),Cenovus Energy&nbsp;(CVE), Carlyle Group (CG),Signature Bank&nbsp;(SBNY),Align Technology&nbsp;(ALGN),Maravai LifeSciences Holdings&nbsp;(MRVI),Fortune Brands Home &amp; Security&nbsp;(FBHS),Shoals Technologies Group&nbsp;(SHLS),CF Industries&nbsp;(CF),Okta&nbsp;(OKTA),Playtika Holding&nbsp;(PLTK), and&nbsp;Republic Services&nbsp;(RSG).</p><p><blockquote>高盛的交易菜单包括星巴克（股票代码：SBUX）、加拿大自然资源公司（CNQ）、YETI Holdings (YETI)、Cenovus Energy (CVE)、凯雷集团（CG）、Signature Bank (SBNY)、Align Technology (ALGN)、Maravai LifeSciences Holdings (MRVI)、Fortune Brands Home &amp; Security (FBHS)、Shoals Technologies Group (SHLS)、CF Industries (CF)、Okta (Okta)、Playtika Holding (PLTK) 和 Republic Services (RSG)。</blockquote></p><p> At a time when so many investors are confused about what to do, Goldman’s approach shows how a sophisticated strategist is thinking when change is in the air and investors are nervous about what comes next.</p><p><blockquote>在许多投资者对该做什么感到困惑的时候，高盛的做法显示了一位老练的策略师在变革即将来临、投资者对接下来会发生什么感到紧张时是如何思考的。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/how-options-investors-should-play-this-earnings-season-51634196601?mod=hp_LATEST\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CG":"凯雷",".SPX":"S&P 500 Index","SBNY":"签字银行","CF":"CF工业","SBUX":"星巴克","SHLS":"Shoals Technologies Group","YETI":"YETI Holdings Inc.","CNQ":"加国自然资源",".DJI":"道琼斯","ALGN":"艾利科技","PLTK":"Playtika Holding Corp.","OKTA":"Okta Inc.","CVE":"Cenovus能源",".IXIC":"NASDAQ Composite","RSG":"共和废品处理","MRVI":"Maravai LifeSciences Holdings, Inc."},"source_url":"https://www.barrons.com/articles/how-options-investors-should-play-this-earnings-season-51634196601?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161146997","content_text":"At the start of the third-quarter earnings season, let it be said that investors are nervous, analysts are generally worried about earnings growth, and the options market is a cauldron of coiled anxiety.\nThe cause for this sour sentiment? Expectations that the Federal Reserve may soon raise interest rates, for a variety of reasons.\nThe economy is beset by inflationary pressures. Supply chains are struggling to keep pace with consumer and corporate demand for everything from semiconductors to toilet paper. Economic growth, which ultimately drives corporate earnings, appears to be slowing, and that generally portends poorly for stock prices. The drama in Washington over raising the debt ceiling, and dueling legislative agendas, adds a circus-like air to the market.\nWhat is less discussed is that the rules of the game are changing. When the Fed finally raises interest rates, most investors will have to learn some new tricks.\nAfter 20 years of easy-money policies, investors have come to rely on the mighty “Fed put”—the belief that the Fed will do whatever it takes to keep the stock market from falling too far. Now, it seems the Fed put might expire after this earnings season, and making money in the stock and options markets may no longer be so easy.\nThe good news? There are ways to monetize these unusual conditions during an event-heavy calendar.\nThere are many crosscurrents moving above and below the market’s surface. The S&P 500 index is dancing around historic highs. Yet earnings estimates for the third quarter show little expectation that corporate earnings reports will prove to be much of anything—and this could create some opportunities for aggressive investors.\nJohn Marshall,Goldman Sachs’ derivatives strategist, recently advised clients that analyst estimates for the third quarter have been revised upward by 12% over the past three months but still remain 2% below the second-quarter’s level (not including the financial sector).\nMeanwhile, single-stock skew—the difference between bearish put-option and bullish call-option implied volatility—is at the highest level in over a year.\nThe elevated skew suggests that investors have bought bearish puts to hedge earnings reports, thus creating conditions that could spark relief rallies in certain stocks on earnings day, and even in broad indexes, Marshall told clients. Investors are so pessimistic about corporate earnings—and have positioned that way in the options market—that any bit of good news could prompt strong moves in individual stocks.\nTo trade these conditions, Marshall has assembled a list of stocks in which Goldman analysts are the most out of consensus with the Street view. On stocks that have the potential to beat earnings estimates, he has suggested that clients consider buying calls that expire in one month, with strike prices just above the current stock price.\nGoldman’s trading menu for stocks with potential upside to earnings estimates includes Starbucks (ticker: SBUX),Canadian Natural Resources (CNQ), YETI Holdings (YETI),Cenovus Energy (CVE), Carlyle Group (CG),Signature Bank (SBNY),Align Technology (ALGN),Maravai LifeSciences Holdings (MRVI),Fortune Brands Home & Security (FBHS),Shoals Technologies Group (SHLS),CF Industries (CF),Okta (OKTA),Playtika Holding (PLTK), and Republic Services (RSG).\nAt a time when so many investors are confused about what to do, Goldman’s approach shows how a sophisticated strategist is thinking when change is in the air and investors are nervous about what comes next.","news_type":1,"symbols_score_info":{"OKTA":0.9,"PLTK":0.9,"MRVI":0.9,".SPX":0.9,".IXIC":0.9,"CG":0.9,"FBHS":0.9,"SBNY":0.9,"SBUX":0.9,"ALGN":0.9,"CNQ":0.9,"SHLS":0.9,"RSG":0.9,"YETI":0.9,"CF":0.9,".DJI":0.9,"CVE":0.9}},"isVote":1,"tweetType":1,"viewCount":2590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820305904,"gmtCreate":1633349666829,"gmtModify":1633351599098,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"IMO&nbsp;Index or theme ETF (e g. ESG)&nbsp;is more stable rather than sector ETF ..... for long term. Commission &amp;&nbsp;Tax will eat into profit for short term&nbsp;as well.","listText":"IMO&nbsp;Index or theme ETF (e g. ESG)&nbsp;is more stable rather than sector ETF ..... for long term. Commission &amp;&nbsp;Tax will eat into profit for short term&nbsp;as well.","text":"IMO Index or theme ETF (e g. ESG) is more stable rather than sector ETF ..... for long term. Commission & Tax will eat into profit for short term as well.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820305904","repostId":"1145081858","repostType":4,"isVote":1,"tweetType":1,"viewCount":3604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862916578,"gmtCreate":1632828366218,"gmtModify":1632828366543,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"20% will be good for those with cash to buy the dip and DCA down. Wish it come through","listText":"20% will be good for those with cash to buy the dip and DCA down. Wish it come through","text":"20% will be good for those with cash to buy the dip and DCA down. Wish it come through","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862916578","repostId":"1166571782","repostType":4,"repost":{"id":"1166571782","kind":"news","pubTimestamp":1632787589,"share":"https://www.laohunote.com/m/news/1166571782?lang=zh_CN&edition=full","pubTime":"2021-09-28 08:06","market":"us","language":"en","title":"Morgan Stanley Dismisses Market's \"Strong Rebound\", Remains Bearish On Coming Earnings Disappointment<blockquote>摩根士丹利对市场“强劲反弹”不屑一顾，对即将到来的盈利令人失望仍然看跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1166571782","media":"zerohedge","summary":"For just a few hours last Monday, Morgan Stanley's chief economist felt vindicated: with stocks tumb","content":"<p>For just a few hours last Monday, Morgan Stanley's chief economist felt vindicated: with stocks tumbling on Evergrande default fears, Wilson emerged from his faux-bull cocoon (havingraised his year-end S&amp;P price target from 3,900 to 4,000 in Augustin a note that reeked of disgust with what he was being told to do) and warned that an \"Ice is coming\", referring to a 20% drop in stocks as opposed to the more modest 10% correction envisioned in his \"fire\" scenario, saying that \"<b>the \"ice\" scenario is starting to look more likely, and could result in a more destructive outcome – i.e. a 20%+ correction</b>\", a drop he expects will take place some time this fall.</p><p><blockquote>上周一短短几个小时内，摩根士丹利首席经济学家就觉得自己是对的：随着股市因恒大违约担忧而暴跌，威尔逊从他的假牛茧中走了出来（他在奥古斯丁将标准普尔年终目标价从 3,900 美元上调至 4,000 美元），并警告说“冰即将来临”，指的是股市下跌 20%，而不是他在“火灾”情景中设想的更温和的 10% 调整，他说“<b>“冰”情景开始看起来更有可能，并可能导致更具破坏性的结果——即20%以上的修正</b>”，他预计今年秋天的某个时候会出现下降。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d87b7fac22f1a1f5db68fec641fc7528\" tg-width=\"703\" tg-height=\"363\" referrerpolicy=\"no-referrer\">Wilson also predicted that with earnings growth and PMIs set to drop, it would adversely impact forward PE multiples and by extension the S&amp;P.</p><p><blockquote>威尔逊还预测，随着盈利增长和采购经理人指数下降，这将对远期市盈率产生不利影响，进而对标准普尔产生不利影响。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/45afcf0068538b4f56bc85f42af9e52f\" tg-width=\"1233\" tg-height=\"431\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Well, what a difference 7 days makes: with Evergrande default fears now long forgotten with little to no offshore contagion,&nbsp;the S&amp;P is almost 150 points from its \"Evergrande Monday\" lows and once again pushing back toward all time highs (even if with a major rotation in the leadership as tech stocks are now sliding, having been replaced by value, cyclical and reopening names) in the process yet again foiling Wilson's bearish visions.</p><p><blockquote>好吧，7 天带来了多么大的不同：随着恒大违约担忧早已被遗忘，几乎没有离岸传染，标准普尔指数距离“恒大周一”低点近 150 点，并再次推回历史高点（即使随着科技股下滑，领导层出现重大轮换，已被价值、周期性和重新开放的名称所取代）在此过程中再次挫败了威尔逊的看跌愿景。</blockquote></p><p> So has the market's sharp post-opex bounce changed the mind of the chief strategist that this seemingly invincible market will never go down again more than just a token 5% move?</p><p><blockquote>那么，市场在运营支出后的大幅反弹是否改变了首席策略师的想法，即这个看似不可战胜的市场除了象征性的 5% 波动之外永远不会再次下跌？</blockquote></p><p> Today we got the answer in Wilson's latest weekly warm-up not, in which he makes it clear that his bearish outlook remains, and as he explains, \"our process tells us the risk-reward remains unattractive at the index level given slowing growth and rising rates. Meanwhile, price action can be interpreted bullishly or bearishly.&nbsp;<b>With 3Q earnings season likely to bring a much more muted outcome, we remain defensive in our positioning.</b>\"</p><p><blockquote>今天，我们在威尔逊最新的每周热身中得到了答案，他在热身中明确表示他的看跌前景仍然存在，正如他解释的那样，“我们的过程告诉我们，鉴于增长放缓和利率上升，风险回报在指数水平上仍然没有吸引力。与此同时，价格走势可以被解释为看涨或看跌。<b>由于第三季度财报季可能会带来更加平淡的结果，我们在定位上保持防御性。</b>\"</blockquote></p><p> We'll get to why in a second, but first Wilson - realizing that he would get a criticism for what many viewed as a premature victory lap - spends the first few paragraphs of his latest note going over the details of his analytical process. This is how he lays it out:</p><p><blockquote>我们稍后会明白为什么，但首先威尔逊——意识到他会因为许多人认为过早的胜利圈而受到批评——在他最新笔记的前几段中详细介绍了他的分析过程。他是这样说的：</blockquote></p><p>   <b>Our equity strategy process has several key components. Most importantly, we focus on the fundamentals of growth and valuation to determine whether the overall market is attractive and which sectors and stocks look the best/worst.</b>The rate of change on growth is more important than the absolute level, and we use a market-based equity risk premium framework that works well as long as you apply the correct regime when using it. In that regard, we’re an avid student of market cycles and believe historical analogs can be helpful. For example, the mid cycle transition narrative that has worked so well this year is derived directly from our study of historical economic and market cycles.    <b>The final component we spend a lot of time on is price.</b>While most would call this technical analysis, we’d like to think we do it a little bit differently. Markets aren’t always efficient, but we believe they are often very good leading indicators for the fundamentals—the ultimate driver of value. This is especially true if one looks at the internal movements and relative strength of individual securities. In short,   <b>we find these internals to be much more helpful than simply looking at the major averages.</b>    <b>This year, we think the process has lived up to its promise quite well with the price action lining up nicely with the fundamental backdrop.</b>In short, the large cap quality leadership since March is signaling what we believe is about to happen—i.e., decelerating growth and tightening financial conditions. The question for investors is whether the price action has fully discounted those outcomes.  With that disclosure in hand, and with the clear understanding that at least in his view investors are not discounting any adverse outcomes at this point, Wilson proceeds to discuss the recent market action, noting that stocks<b>\"sold off hard last Monday on concerns about the Evergrande bankruptcy\"</b>and while he adds that it is the Morgan Stanley \"house view\" that it likely won’t lead to a major financial contagion, \"it will probably weigh on China growth for the next few quarters which means that the growth deceleration we are expecting could be a bit worse.\"</p><p><blockquote><b>我们的股权战略流程有几个关键组成部分。最重要的是，我们关注增长和估值的基本面，以确定整体市场是否有吸引力，以及哪些行业和股票看起来最好/最差。</b>增长率的变化率比绝对水平更重要，我们使用基于市场的股票风险溢价框架，只要您在使用时应用正确的制度，该框架就能很好地工作。在这方面，我们热衷于研究市场周期，并相信历史类比会有所帮助。例如，今年非常有效的中周期转型叙事直接来自我们对历史经济和市场周期的研究。<b>我们花费大量时间的最后一个组成部分是价格。</b>虽然大多数人会看涨期权这种技术分析，但我们认为我们的做法略有不同。市场并不总是有效的，但我们相信，市场往往是基本面--价值的最终驱动力--非常好的领先指标。如果看看个别证券的内部变动和相对强度，情况尤其如此。简而言之，<b>我们发现这些内部因素比简单地查看主要平均值更有帮助。</b><b>今年，我们认为这一过程很好地兑现了其承诺，价格走势与基本面背景非常吻合。</b>简而言之，自3月份以来的大盘股质量领先地位预示着我们认为即将发生的事情——即增长放缓和金融状况收紧。投资者面临的问题是价格走势是否完全打折了这些结果。有了这一披露，并且清楚地认识到，至少在他看来，投资者目前并没有忽视任何不利结果，威尔逊继续讨论最近的市场走势，并指出股票<b>“上周一因担心恒大破产而大幅抛售”</b>虽然他补充说，摩根士丹利的 “众议院观点 ”认为，这可能不会导致重大的金融传染，但 “这可能会拖累中国未来几个季度的经济增长，这意味着我们预期的经济增长放缓可能会更严重一些”。</blockquote></p><p></p><p> The other reason Wilson suggests was behind the market weakness early last week \"likely had to do with concern about the Fed articulating its plans to taper asset purchases later this year and perhaps even move up the timing of rate hikes to next year. On that score, the Fed did not disappoint as they pretty much told us to expect the taper to begin in December.<b>The surprise was the speed in which they expect to be done tapering—by mid 2022.</b>This is about a quarter sooner than the market had been anticipating and does move up the odds for a rate hike in 2022.\"</p><p><blockquote>威尔逊认为，上周早些时候市场疲软背后的另一个原因“可能与对美联储在今年晚些时候阐述其缩减资产购买计划的担忧有关，甚至可能将加息时间提前到明年。在这一点上，美联储没有让人失望，因为他们几乎告诉我们预计缩减规模将于12月开始。<b>令人惊讶的是他们预计缩减规模的速度——到 2022 年中期。</b>这比市场预期提前了约四分之一，确实增加了 2022 年加息的可能性。”</blockquote></p><p> Curiously last week's rally happened in the aftermath of the market's perplexing kneejerk response to the Fed meeting on Wednesday, when stocks rallied even as bonds sold off sharply, particularly at the back end. Real 10-year yields were up 11bps in 2 days and are now up 31bps in just 8 weeks (Exhibit 1). That according to Wilson is \"tightening of financial conditions for sure\" and should weigh on PEs overall but it also has big implications for what should work at the sector/style level (Exhibit 2).</p><p><blockquote>奇怪的是，上周的反弹发生在市场对周三美联储会议做出令人困惑的下意识反应之后，当时尽管债券大幅抛售，尤其是在后端，股市仍反弹。实际10年期国债收益率在2天内上升了11个基点，现在在短短8周内上升了31个基点（图表1）。根据威尔逊的说法，这“肯定是金融状况的收紧”，应该会对整体私募股权基金造成压力，但它也对行业/风格层面的表现产生了重大影响（图表2）。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b6f0bb937e8d564694c06b7e1362bd81\" tg-width=\"1035\" tg-height=\"266\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> In short, Wilson digs in and claims that higher real rates should mean lower P/Es overall which likely means lower S&amp;P 500, thus validating his bearish view which still sees the S&amp;P dropping some 20% from its current perch to hit 4,000 by year end. However, he concedes, \"it may also mean value over growth and small caps over Nasdaq even as the overall equity market goes lower.\"</p><p><blockquote>简而言之，Wilson深入探讨并声称，较高的实际利率应该意味着整体市盈率较低，这可能意味着标普500较低，从而验证了他的看跌观点，即标准普尔指数仍将从目前的水平下跌约20%，到年底达到4000点。然而，他承认，“即使整体股市走低，这也可能意味着价值高于增长，小盘股高于纳斯达克。”</blockquote></p><p> Which brings us to the key question we spent quite some time discussing last week, namely<b>why did stocks rally so much into the end of the week</b>on what Wilson says are odds that growth will decelerate more than expected from Evergrande and financial conditions may tighten faster?</p><p><blockquote>这就引出了我们上周花了相当多时间讨论的关键问题，即<b>为什么股市在周末上涨如此之多</b>威尔逊表示，恒大的增长放缓幅度将超过预期，财务状况可能会更快收紧？</blockquote></p><p> Here Wilson is at least honest - as he puts it - and says \"we’re not sure but we think this may be a time when the markets are playing tricks on investors and even setting a bit of a trap.\" Actually it's simpler than that and has to do with thegamma reversal and technical flows we pointed out last week, but one has to be a \"greek geek\" - like Nomura's Charlie McElligott - to get that.</p><p><blockquote>在这里，威尔逊至少是诚实的--正如他所说--他说：“我们不确定，但我们认为这可能是市场在捉弄投资者，甚至设置一点陷阱的时候。”实际上，它比这更简单，与我们上周指出的伽马反转和技术流程有关，但人们必须是一个“希腊极客”——比如野村证券的查理·麦切利戈特——才能理解这一点。</blockquote></p><p> The other explanation proposed by Wilson is \"that investors were somewhat positioned for bad news going into the Fed meeting and the actual event simply served as a relief that it didn’t lead lower prices. This price action drove many investors to chase on Thursday for fear of missing out.<b>In short, don’t underestimate the power of price to determine how investors interpret the facts.</b>Just like negative price action can get people to sell the lows, positive price action can force people to buy\", he concludes.</p><p><blockquote>威尔逊提出的另一种解释是：“投资者在美联储会议上对坏消息有所准备，而实际事件只是让人松了一口气，因为它没有导致价格下跌。这一价格走势促使许多投资者在周四追涨，生怕错过机会。<b>简而言之，不要低估价格在决定投资者如何解读事实方面的力量。</b>正如负价格行为可以让人们低价抛售一样，正价格行为也可以迫使人们买入”，他总结道。</blockquote></p><p> Whatever the reason for the initial bounce, it quickly accelerated and there was \"a lot of excitement last Thursday when stocks rallied sharply back above the 50 day moving average, a key barometer for many and a key level of support throughout this year for the S&amp;P 500.\" That this happened when the 50DMA was broken \"on near record levels of volume in both the cash and derivatives markets\" only punctuated the strength of the rebound. By Friday, that moving average had been reclaimed and closed above it for the week, an important technical win as even Wilson admits. However, he then adds, from his vantage point, \"the very well defined uptrend that has been established over the past year was broken and not reclaimed. Instead, it looks like the rally from Wednesday to Friday was simply \"filling the gap\" created from Monday's break.\"</p><p><blockquote>无论最初反弹的原因是什么，反弹很快就加速了，“上周四，当股市大幅反弹至 50 日移动平均线上方时，人们非常兴奋，这对许多人来说是一个关键晴雨表，也是标普500今年全年的一个关键支撑位。”当 50DMA 被突破“现金和衍生品市场的交易量均接近创纪录水平”时，这种情况就发生了，这只会削弱反弹的强度。到周五，移动平均线已被收复，并在本周收于该平均线之上，就连威尔逊也承认，这是一次重要的技术胜利。然而，他随后补充道，从他的有利位置来看，“过去一年建立的非常明确的上升趋势被打破了，并且没有重新夺回。相反，看起来周三到周五的反弹只是“填补”周一休息造成的缺口。”</blockquote></p><p> His conclusion on upcoming market action will hardly come as a surprise to those who have followed Wilson's progressive pessimism across 2021: pointing to the market's inability to recover its prior trendline, he says \"this leaves the technical picture very uncertain in our view and one can now break either way. With our fundamental view skewing poorly at the moment, we lean to the bearish outcome.\"</p><p><blockquote>对于那些在 2021 年关注威尔逊逐渐悲观情绪的人来说，他对即将到来的市场行动的结论几乎不会感到惊讶：他指出市场无法恢复之前的趋势线，他表示：“这使得我们认为技术面非常不确定，现在可以打破任何一方。由于我们的基本面观点目前严重扭曲，我们倾向于看跌结果。”</blockquote></p><p> <img src=\"https://static.tigerbbs.com/41fc56e35f140c96104f8d8aa0826fd3\" tg-width=\"1100\" tg-height=\"602\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Getting back to his process, Wilson then says that he has high conviction that \"earnings growth is likely to decelerate more than what the current consensus is forecasting.\" Furthermore, he thinks the market is starting to agree with that view and points to market breadth as a good leading indicator for earnings revision breadth where he says \"direction is clear\" and pointing to the newly shrinking market breadth, he reminds readers that earnings revision breadth is a good leading indicator for the overall market.</p><p><blockquote>回到他的流程，威尔逊随后表示，他坚信“盈利增长可能会比当前共识预测的放缓幅度更大”。此外，他认为市场开始同意这一观点，并指出市场广度是盈利修正广度的良好领先指标，他表示“方向很明确”，并指出新收缩的市场广度，他提醒读者盈利修正广度是整体市场的良好领先指标。</blockquote></p><p></p><p> It will therefore hardly come as a surprise that with Wilson still clearly bearish, his advice to clients is \"<b>don’t get too caught up in last week’s strong rebound from Monday’s sharp sell off\"</b>which he views as a clean break of the uptrend and a filling of the gap created from Monday's crack. And with the technical picture murky, \"<b>that's a time to trust the fundamental and cycle analyses which suggest lower equity prices ahead\"</b>and as growth decelerates and financial conditions tighten, valuations are likely to fall from their lofty levels.</p><p><blockquote>因此，威尔逊仍然明显看空，他给客户的建议是“<b>不要被上周从周一的大幅抛售中强劲反弹所迷惑”</b>他认为这是对上升趋势的彻底打破，也是对周一裂缝造成的缺口的填补。由于技术方面的情况不明朗，”<b>现在是相信基本面和周期分析表明未来股价走低的时候了”</b>随着经济增长放缓和金融状况收紧，估值可能会从高位回落。</blockquote></p><p> * * *</p><p><blockquote>***</blockquote></p><p> With all that in mind, Wilson goes back to his core fundamental thesis which is simple: after a blockbuster Q2 season, earnings are set to drop substantially as a result of the margin compression we discussed most recently over the weekend, to wit:</p><p><blockquote>考虑到所有这些，威尔逊回到了他的核心基本论点，这个论点很简单：在经历了一个轰动一时的第二季度之后，由于我们最近在周末讨论的利润率压缩，盈利将大幅下降，也就是说：</blockquote></p><p>   <b>Since the second quarter of 2020 earnings results have come in much higher than consensus forecasts</b>. Earnings beats ranged from 14% - 22% over this period while the median beat rate since 2008 is only 5%...We do not think companies will continue to beat at such an unprecedented rate and believe 3Q could see a material change in the more recent trend as supply chain issues and labor shortages pose a risk to both top line and margins.  <img src=\"https://static.tigerbbs.com/f5e643723cfa540ad52a1dcebcba24f3\" tg-width=\"722\" tg-height=\"433\" referrerpolicy=\"no-referrer\"></p><p><blockquote><b>自 2020 年第二季度以来，盈利结果远高于市场普遍预期</b>在此期间，盈利超出率在 14% 至 22% 之间，而自 2008 年以来的中值超出率仅为 5%……我们认为公司不会继续以如此前所未有的速度超出预期，并相信第三季度可能会出现重大变化近期趋势，因为供应链问题和劳动力短缺对营收和利润率都构成风险。</blockquote></p><p>   We looked at how 3Q earnings estimate revisions have trended at the industry group and sector level. Significant cuts have occurred in insurance, capital goods and transportation.   <b>Consumer Durables is the only area that has seen significant positive revisions at the industry group level. 3Q S&amp;P 500 estimates have fallen by 77 bps over past 4 weeks. We expect more downside.</b>  <img src=\"https://static.tigerbbs.com/c5496394c7a42ab136f68ba74c64cf83\" tg-width=\"705\" tg-height=\"451\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/ef6beae58fd458a45024d160d45b4684\" tg-width=\"735\" tg-height=\"459\" referrerpolicy=\"no-referrer\"></p><p><blockquote>我们研究了第三季度盈利预测修正在行业集团和行业层面的趋势。保险、资本货物和运输都出现了大幅削减。<b>耐用消费品是行业集团层面唯一出现重大积极修正的领域。过去 4 周内，第三季度标普500预期下降了 77 个基点。我们预计会有更多的负面影响。</b></blockquote></p><p> No surprises there, as the margin compression story is a familiar one (\"Margins Crushed As Producer Prices Explode At Record Pace In July\"). To Wilson, however, this is the story and one which the market refuses to even consider:</p><p><blockquote>这并不奇怪，因为利润率压缩的故事是一个熟悉的故事（“随着 7 月份生产者价格以创纪录的速度爆炸，利润率被压缩”）。然而，对于威尔逊来说，这是一个故事，也是一个市场甚至拒绝考虑的故事：</blockquote></p><p> <b>2022 consensus margin estimates are historically lofty...</b>we examine the risks to margins in coming quarters through two different top down approaches. The spread between GDP growth and wage growth correlates fairly closely with operating margins over time. Based on our economists' estimates<b>, this spread should decelerate in coming quarters, which suggests margins should contract, not expand as bottom-up consensus expects</b>.</p><p><blockquote><b>2022 年共识利润率估计处于历史高位……</b>我们通过两种不同的自上而下的方法来研究未来几个季度的利润率风险。随着时间的推移，GDP增长和工资增长之间的利差与营业利润率密切相关。根据我们经济学家的估计<b>这种利差应该会在未来几个季度放缓，这表明利润率应该会收缩，而不是像自下而上的共识预期那样扩大</b>.</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e80ec048b5856ebf2159d1d9d0151334\" tg-width=\"751\" tg-height=\"578\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Further, corporate transcript mentions of \"cost pressures\" and related terms are historically elevated. When this has happened in the past, margins have consolidated.</p><p><blockquote>此外，公司成绩单中对“成本压力”和相关术语的提及历来较高。当这种情况在过去发生时，利润率已经巩固。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/42c8fcfa4bb23d953d8c2079bc1a0ec5\" tg-width=\"773\" tg-height=\"540\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Wilson's final bearish point is that companies are reaching the limit on how much of rising input costs they can pass on to consumers. As he puts it, while \"many investors that we speak to are optimistic about corporates' ability to pass on cost through pricing and protect margins\" he would caution that \"prices in several consumer end markets are already at a level that is inhibiting demand. We think the risk of this dynamic (high prices leading to demand destruction) spreading to other areas of consumer demand is especially elevated because goods consumption is already so far above trend—<b>in other words, high prices are that much more of a deterrent given households have already overconsumed in many areas.\"</b></p><p><blockquote>威尔逊的最后一个悲观观点是，企业已经达到了将不断上涨的投入成本转嫁给消费者的极限。正如他所说，虽然“我们采访的许多投资者对企业通过定价转嫁成本和保护利润率的能力持乐观态度”，但他会警告说，“几个消费终端市场的价格已经处于抑制需求的水平。我们认为，这种动态（高价格导致需求破坏）蔓延到其他消费需求领域的风险尤其高，因为商品消费已经远远高于趋势——<b>换句话说，考虑到许多地区的家庭已经过度消费，高价格更具威慑力。”</b></blockquote></p><p> <img src=\"https://static.tigerbbs.com/216bbe5eae73445b35a9152e741dccef\" tg-width=\"1009\" tg-height=\"801\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Translation: absent another multi-trillion stimmy - and thanks to the chaos in the democratic party we know one is unlikely to come - Wilson's call for a 20% drop in stocks in the next few months remains intact.</p><p><blockquote>翻译：如果没有另一场数万亿的骚动——由于民主党内部的混乱，我们知道不太可能发生——威尔逊关于未来几个月股市下跌 20% 的看涨期权仍然完好无损。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley Dismisses Market's \"Strong Rebound\", Remains Bearish On Coming Earnings Disappointment<blockquote>摩根士丹利对市场“强劲反弹”不屑一顾，对即将到来的盈利令人失望仍然看跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley Dismisses Market's \"Strong Rebound\", Remains Bearish On Coming Earnings Disappointment<blockquote>摩根士丹利对市场“强劲反弹”不屑一顾，对即将到来的盈利令人失望仍然看跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">zerohedge</strong><span class=\"h-time small\">2021-09-28 08:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p>For just a few hours last Monday, Morgan Stanley's chief economist felt vindicated: with stocks tumbling on Evergrande default fears, Wilson emerged from his faux-bull cocoon (havingraised his year-end S&amp;P price target from 3,900 to 4,000 in Augustin a note that reeked of disgust with what he was being told to do) and warned that an \"Ice is coming\", referring to a 20% drop in stocks as opposed to the more modest 10% correction envisioned in his \"fire\" scenario, saying that \"<b>the \"ice\" scenario is starting to look more likely, and could result in a more destructive outcome – i.e. a 20%+ correction</b>\", a drop he expects will take place some time this fall.</p><p><blockquote>上周一短短几个小时内，摩根士丹利首席经济学家就觉得自己是对的：随着股市因恒大违约担忧而暴跌，威尔逊从他的假牛茧中走了出来（他在奥古斯丁将标准普尔年终目标价从 3,900 美元上调至 4,000 美元），并警告说“冰即将来临”，指的是股市下跌 20%，而不是他在“火灾”情景中设想的更温和的 10% 调整，他说“<b>“冰”情景开始看起来更有可能，并可能导致更具破坏性的结果——即20%以上的修正</b>”，他预计今年秋天的某个时候会出现下降。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d87b7fac22f1a1f5db68fec641fc7528\" tg-width=\"703\" tg-height=\"363\" referrerpolicy=\"no-referrer\">Wilson also predicted that with earnings growth and PMIs set to drop, it would adversely impact forward PE multiples and by extension the S&amp;P.</p><p><blockquote>威尔逊还预测，随着盈利增长和采购经理人指数下降，这将对远期市盈率产生不利影响，进而对标准普尔产生不利影响。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/45afcf0068538b4f56bc85f42af9e52f\" tg-width=\"1233\" tg-height=\"431\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Well, what a difference 7 days makes: with Evergrande default fears now long forgotten with little to no offshore contagion,&nbsp;the S&amp;P is almost 150 points from its \"Evergrande Monday\" lows and once again pushing back toward all time highs (even if with a major rotation in the leadership as tech stocks are now sliding, having been replaced by value, cyclical and reopening names) in the process yet again foiling Wilson's bearish visions.</p><p><blockquote>好吧，7 天带来了多么大的不同：随着恒大违约担忧早已被遗忘，几乎没有离岸传染，标准普尔指数距离“恒大周一”低点近 150 点，并再次推回历史高点（即使随着科技股下滑，领导层出现重大轮换，已被价值、周期性和重新开放的名称所取代）在此过程中再次挫败了威尔逊的看跌愿景。</blockquote></p><p> So has the market's sharp post-opex bounce changed the mind of the chief strategist that this seemingly invincible market will never go down again more than just a token 5% move?</p><p><blockquote>那么，市场在运营支出后的大幅反弹是否改变了首席策略师的想法，即这个看似不可战胜的市场除了象征性的 5% 波动之外永远不会再次下跌？</blockquote></p><p> Today we got the answer in Wilson's latest weekly warm-up not, in which he makes it clear that his bearish outlook remains, and as he explains, \"our process tells us the risk-reward remains unattractive at the index level given slowing growth and rising rates. Meanwhile, price action can be interpreted bullishly or bearishly.&nbsp;<b>With 3Q earnings season likely to bring a much more muted outcome, we remain defensive in our positioning.</b>\"</p><p><blockquote>今天，我们在威尔逊最新的每周热身中得到了答案，他在热身中明确表示他的看跌前景仍然存在，正如他解释的那样，“我们的过程告诉我们，鉴于增长放缓和利率上升，风险回报在指数水平上仍然没有吸引力。与此同时，价格走势可以被解释为看涨或看跌。<b>由于第三季度财报季可能会带来更加平淡的结果，我们在定位上保持防御性。</b>\"</blockquote></p><p> We'll get to why in a second, but first Wilson - realizing that he would get a criticism for what many viewed as a premature victory lap - spends the first few paragraphs of his latest note going over the details of his analytical process. This is how he lays it out:</p><p><blockquote>我们稍后会明白为什么，但首先威尔逊——意识到他会因为许多人认为过早的胜利圈而受到批评——在他最新笔记的前几段中详细介绍了他的分析过程。他是这样说的：</blockquote></p><p>   <b>Our equity strategy process has several key components. Most importantly, we focus on the fundamentals of growth and valuation to determine whether the overall market is attractive and which sectors and stocks look the best/worst.</b>The rate of change on growth is more important than the absolute level, and we use a market-based equity risk premium framework that works well as long as you apply the correct regime when using it. In that regard, we’re an avid student of market cycles and believe historical analogs can be helpful. For example, the mid cycle transition narrative that has worked so well this year is derived directly from our study of historical economic and market cycles.    <b>The final component we spend a lot of time on is price.</b>While most would call this technical analysis, we’d like to think we do it a little bit differently. Markets aren’t always efficient, but we believe they are often very good leading indicators for the fundamentals—the ultimate driver of value. This is especially true if one looks at the internal movements and relative strength of individual securities. In short,   <b>we find these internals to be much more helpful than simply looking at the major averages.</b>    <b>This year, we think the process has lived up to its promise quite well with the price action lining up nicely with the fundamental backdrop.</b>In short, the large cap quality leadership since March is signaling what we believe is about to happen—i.e., decelerating growth and tightening financial conditions. The question for investors is whether the price action has fully discounted those outcomes.  With that disclosure in hand, and with the clear understanding that at least in his view investors are not discounting any adverse outcomes at this point, Wilson proceeds to discuss the recent market action, noting that stocks<b>\"sold off hard last Monday on concerns about the Evergrande bankruptcy\"</b>and while he adds that it is the Morgan Stanley \"house view\" that it likely won’t lead to a major financial contagion, \"it will probably weigh on China growth for the next few quarters which means that the growth deceleration we are expecting could be a bit worse.\"</p><p><blockquote><b>我们的股权战略流程有几个关键组成部分。最重要的是，我们关注增长和估值的基本面，以确定整体市场是否有吸引力，以及哪些行业和股票看起来最好/最差。</b>增长率的变化率比绝对水平更重要，我们使用基于市场的股票风险溢价框架，只要您在使用时应用正确的制度，该框架就能很好地工作。在这方面，我们热衷于研究市场周期，并相信历史类比会有所帮助。例如，今年非常有效的中周期转型叙事直接来自我们对历史经济和市场周期的研究。<b>我们花费大量时间的最后一个组成部分是价格。</b>虽然大多数人会看涨期权这种技术分析，但我们认为我们的做法略有不同。市场并不总是有效的，但我们相信，市场往往是基本面--价值的最终驱动力--非常好的领先指标。如果看看个别证券的内部变动和相对强度，情况尤其如此。简而言之，<b>我们发现这些内部因素比简单地查看主要平均值更有帮助。</b><b>今年，我们认为这一过程很好地兑现了其承诺，价格走势与基本面背景非常吻合。</b>简而言之，自3月份以来的大盘股质量领先地位预示着我们认为即将发生的事情——即增长放缓和金融状况收紧。投资者面临的问题是价格走势是否完全打折了这些结果。有了这一披露，并且清楚地认识到，至少在他看来，投资者目前并没有忽视任何不利结果，威尔逊继续讨论最近的市场走势，并指出股票<b>“上周一因担心恒大破产而大幅抛售”</b>虽然他补充说，摩根士丹利的 “众议院观点 ”认为，这可能不会导致重大的金融传染，但 “这可能会拖累中国未来几个季度的经济增长，这意味着我们预期的经济增长放缓可能会更严重一些”。</blockquote></p><p></p><p> The other reason Wilson suggests was behind the market weakness early last week \"likely had to do with concern about the Fed articulating its plans to taper asset purchases later this year and perhaps even move up the timing of rate hikes to next year. On that score, the Fed did not disappoint as they pretty much told us to expect the taper to begin in December.<b>The surprise was the speed in which they expect to be done tapering—by mid 2022.</b>This is about a quarter sooner than the market had been anticipating and does move up the odds for a rate hike in 2022.\"</p><p><blockquote>威尔逊认为，上周早些时候市场疲软背后的另一个原因“可能与对美联储在今年晚些时候阐述其缩减资产购买计划的担忧有关，甚至可能将加息时间提前到明年。在这一点上，美联储没有让人失望，因为他们几乎告诉我们预计缩减规模将于12月开始。<b>令人惊讶的是他们预计缩减规模的速度——到 2022 年中期。</b>这比市场预期提前了约四分之一，确实增加了 2022 年加息的可能性。”</blockquote></p><p> Curiously last week's rally happened in the aftermath of the market's perplexing kneejerk response to the Fed meeting on Wednesday, when stocks rallied even as bonds sold off sharply, particularly at the back end. Real 10-year yields were up 11bps in 2 days and are now up 31bps in just 8 weeks (Exhibit 1). That according to Wilson is \"tightening of financial conditions for sure\" and should weigh on PEs overall but it also has big implications for what should work at the sector/style level (Exhibit 2).</p><p><blockquote>奇怪的是，上周的反弹发生在市场对周三美联储会议做出令人困惑的下意识反应之后，当时尽管债券大幅抛售，尤其是在后端，股市仍反弹。实际10年期国债收益率在2天内上升了11个基点，现在在短短8周内上升了31个基点（图表1）。根据威尔逊的说法，这“肯定是金融状况的收紧”，应该会对整体私募股权基金造成压力，但它也对行业/风格层面的表现产生了重大影响（图表2）。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b6f0bb937e8d564694c06b7e1362bd81\" tg-width=\"1035\" tg-height=\"266\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> In short, Wilson digs in and claims that higher real rates should mean lower P/Es overall which likely means lower S&amp;P 500, thus validating his bearish view which still sees the S&amp;P dropping some 20% from its current perch to hit 4,000 by year end. However, he concedes, \"it may also mean value over growth and small caps over Nasdaq even as the overall equity market goes lower.\"</p><p><blockquote>简而言之，Wilson深入探讨并声称，较高的实际利率应该意味着整体市盈率较低，这可能意味着标普500较低，从而验证了他的看跌观点，即标准普尔指数仍将从目前的水平下跌约20%，到年底达到4000点。然而，他承认，“即使整体股市走低，这也可能意味着价值高于增长，小盘股高于纳斯达克。”</blockquote></p><p> Which brings us to the key question we spent quite some time discussing last week, namely<b>why did stocks rally so much into the end of the week</b>on what Wilson says are odds that growth will decelerate more than expected from Evergrande and financial conditions may tighten faster?</p><p><blockquote>这就引出了我们上周花了相当多时间讨论的关键问题，即<b>为什么股市在周末上涨如此之多</b>威尔逊表示，恒大的增长放缓幅度将超过预期，财务状况可能会更快收紧？</blockquote></p><p> Here Wilson is at least honest - as he puts it - and says \"we’re not sure but we think this may be a time when the markets are playing tricks on investors and even setting a bit of a trap.\" Actually it's simpler than that and has to do with thegamma reversal and technical flows we pointed out last week, but one has to be a \"greek geek\" - like Nomura's Charlie McElligott - to get that.</p><p><blockquote>在这里，威尔逊至少是诚实的--正如他所说--他说：“我们不确定，但我们认为这可能是市场在捉弄投资者，甚至设置一点陷阱的时候。”实际上，它比这更简单，与我们上周指出的伽马反转和技术流程有关，但人们必须是一个“希腊极客”——比如野村证券的查理·麦切利戈特——才能理解这一点。</blockquote></p><p> The other explanation proposed by Wilson is \"that investors were somewhat positioned for bad news going into the Fed meeting and the actual event simply served as a relief that it didn’t lead lower prices. This price action drove many investors to chase on Thursday for fear of missing out.<b>In short, don’t underestimate the power of price to determine how investors interpret the facts.</b>Just like negative price action can get people to sell the lows, positive price action can force people to buy\", he concludes.</p><p><blockquote>威尔逊提出的另一种解释是：“投资者在美联储会议上对坏消息有所准备，而实际事件只是让人松了一口气，因为它没有导致价格下跌。这一价格走势促使许多投资者在周四追涨，生怕错过机会。<b>简而言之，不要低估价格在决定投资者如何解读事实方面的力量。</b>正如负价格行为可以让人们低价抛售一样，正价格行为也可以迫使人们买入”，他总结道。</blockquote></p><p> Whatever the reason for the initial bounce, it quickly accelerated and there was \"a lot of excitement last Thursday when stocks rallied sharply back above the 50 day moving average, a key barometer for many and a key level of support throughout this year for the S&amp;P 500.\" That this happened when the 50DMA was broken \"on near record levels of volume in both the cash and derivatives markets\" only punctuated the strength of the rebound. By Friday, that moving average had been reclaimed and closed above it for the week, an important technical win as even Wilson admits. However, he then adds, from his vantage point, \"the very well defined uptrend that has been established over the past year was broken and not reclaimed. Instead, it looks like the rally from Wednesday to Friday was simply \"filling the gap\" created from Monday's break.\"</p><p><blockquote>无论最初反弹的原因是什么，反弹很快就加速了，“上周四，当股市大幅反弹至 50 日移动平均线上方时，人们非常兴奋，这对许多人来说是一个关键晴雨表，也是标普500今年全年的一个关键支撑位。”当 50DMA 被突破“现金和衍生品市场的交易量均接近创纪录水平”时，这种情况就发生了，这只会削弱反弹的强度。到周五，移动平均线已被收复，并在本周收于该平均线之上，就连威尔逊也承认，这是一次重要的技术胜利。然而，他随后补充道，从他的有利位置来看，“过去一年建立的非常明确的上升趋势被打破了，并且没有重新夺回。相反，看起来周三到周五的反弹只是“填补”周一休息造成的缺口。”</blockquote></p><p> His conclusion on upcoming market action will hardly come as a surprise to those who have followed Wilson's progressive pessimism across 2021: pointing to the market's inability to recover its prior trendline, he says \"this leaves the technical picture very uncertain in our view and one can now break either way. With our fundamental view skewing poorly at the moment, we lean to the bearish outcome.\"</p><p><blockquote>对于那些在 2021 年关注威尔逊逐渐悲观情绪的人来说，他对即将到来的市场行动的结论几乎不会感到惊讶：他指出市场无法恢复之前的趋势线，他表示：“这使得我们认为技术面非常不确定，现在可以打破任何一方。由于我们的基本面观点目前严重扭曲，我们倾向于看跌结果。”</blockquote></p><p> <img src=\"https://static.tigerbbs.com/41fc56e35f140c96104f8d8aa0826fd3\" tg-width=\"1100\" tg-height=\"602\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Getting back to his process, Wilson then says that he has high conviction that \"earnings growth is likely to decelerate more than what the current consensus is forecasting.\" Furthermore, he thinks the market is starting to agree with that view and points to market breadth as a good leading indicator for earnings revision breadth where he says \"direction is clear\" and pointing to the newly shrinking market breadth, he reminds readers that earnings revision breadth is a good leading indicator for the overall market.</p><p><blockquote>回到他的流程，威尔逊随后表示，他坚信“盈利增长可能会比当前共识预测的放缓幅度更大”。此外，他认为市场开始同意这一观点，并指出市场广度是盈利修正广度的良好领先指标，他表示“方向很明确”，并指出新收缩的市场广度，他提醒读者盈利修正广度是整体市场的良好领先指标。</blockquote></p><p></p><p> It will therefore hardly come as a surprise that with Wilson still clearly bearish, his advice to clients is \"<b>don’t get too caught up in last week’s strong rebound from Monday’s sharp sell off\"</b>which he views as a clean break of the uptrend and a filling of the gap created from Monday's crack. And with the technical picture murky, \"<b>that's a time to trust the fundamental and cycle analyses which suggest lower equity prices ahead\"</b>and as growth decelerates and financial conditions tighten, valuations are likely to fall from their lofty levels.</p><p><blockquote>因此，威尔逊仍然明显看空，他给客户的建议是“<b>不要被上周从周一的大幅抛售中强劲反弹所迷惑”</b>他认为这是对上升趋势的彻底打破，也是对周一裂缝造成的缺口的填补。由于技术方面的情况不明朗，”<b>现在是相信基本面和周期分析表明未来股价走低的时候了”</b>随着经济增长放缓和金融状况收紧，估值可能会从高位回落。</blockquote></p><p> * * *</p><p><blockquote>***</blockquote></p><p> With all that in mind, Wilson goes back to his core fundamental thesis which is simple: after a blockbuster Q2 season, earnings are set to drop substantially as a result of the margin compression we discussed most recently over the weekend, to wit:</p><p><blockquote>考虑到所有这些，威尔逊回到了他的核心基本论点，这个论点很简单：在经历了一个轰动一时的第二季度之后，由于我们最近在周末讨论的利润率压缩，盈利将大幅下降，也就是说：</blockquote></p><p>   <b>Since the second quarter of 2020 earnings results have come in much higher than consensus forecasts</b>. Earnings beats ranged from 14% - 22% over this period while the median beat rate since 2008 is only 5%...We do not think companies will continue to beat at such an unprecedented rate and believe 3Q could see a material change in the more recent trend as supply chain issues and labor shortages pose a risk to both top line and margins.  <img src=\"https://static.tigerbbs.com/f5e643723cfa540ad52a1dcebcba24f3\" tg-width=\"722\" tg-height=\"433\" referrerpolicy=\"no-referrer\"></p><p><blockquote><b>自 2020 年第二季度以来，盈利结果远高于市场普遍预期</b>在此期间，盈利超出率在 14% 至 22% 之间，而自 2008 年以来的中值超出率仅为 5%……我们认为公司不会继续以如此前所未有的速度超出预期，并相信第三季度可能会出现重大变化近期趋势，因为供应链问题和劳动力短缺对营收和利润率都构成风险。</blockquote></p><p>   We looked at how 3Q earnings estimate revisions have trended at the industry group and sector level. Significant cuts have occurred in insurance, capital goods and transportation.   <b>Consumer Durables is the only area that has seen significant positive revisions at the industry group level. 3Q S&amp;P 500 estimates have fallen by 77 bps over past 4 weeks. We expect more downside.</b>  <img src=\"https://static.tigerbbs.com/c5496394c7a42ab136f68ba74c64cf83\" tg-width=\"705\" tg-height=\"451\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/ef6beae58fd458a45024d160d45b4684\" tg-width=\"735\" tg-height=\"459\" referrerpolicy=\"no-referrer\"></p><p><blockquote>我们研究了第三季度盈利预测修正在行业集团和行业层面的趋势。保险、资本货物和运输都出现了大幅削减。<b>耐用消费品是行业集团层面唯一出现重大积极修正的领域。过去 4 周内，第三季度标普500预期下降了 77 个基点。我们预计会有更多的负面影响。</b></blockquote></p><p> No surprises there, as the margin compression story is a familiar one (\"Margins Crushed As Producer Prices Explode At Record Pace In July\"). To Wilson, however, this is the story and one which the market refuses to even consider:</p><p><blockquote>这并不奇怪，因为利润率压缩的故事是一个熟悉的故事（“随着 7 月份生产者价格以创纪录的速度爆炸，利润率被压缩”）。然而，对于威尔逊来说，这是一个故事，也是一个市场甚至拒绝考虑的故事：</blockquote></p><p> <b>2022 consensus margin estimates are historically lofty...</b>we examine the risks to margins in coming quarters through two different top down approaches. The spread between GDP growth and wage growth correlates fairly closely with operating margins over time. Based on our economists' estimates<b>, this spread should decelerate in coming quarters, which suggests margins should contract, not expand as bottom-up consensus expects</b>.</p><p><blockquote><b>2022 年共识利润率估计处于历史高位……</b>我们通过两种不同的自上而下的方法来研究未来几个季度的利润率风险。随着时间的推移，GDP增长和工资增长之间的利差与营业利润率密切相关。根据我们经济学家的估计<b>这种利差应该会在未来几个季度放缓，这表明利润率应该会收缩，而不是像自下而上的共识预期那样扩大</b>.</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e80ec048b5856ebf2159d1d9d0151334\" tg-width=\"751\" tg-height=\"578\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Further, corporate transcript mentions of \"cost pressures\" and related terms are historically elevated. When this has happened in the past, margins have consolidated.</p><p><blockquote>此外，公司成绩单中对“成本压力”和相关术语的提及历来较高。当这种情况在过去发生时，利润率已经巩固。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/42c8fcfa4bb23d953d8c2079bc1a0ec5\" tg-width=\"773\" tg-height=\"540\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Wilson's final bearish point is that companies are reaching the limit on how much of rising input costs they can pass on to consumers. As he puts it, while \"many investors that we speak to are optimistic about corporates' ability to pass on cost through pricing and protect margins\" he would caution that \"prices in several consumer end markets are already at a level that is inhibiting demand. We think the risk of this dynamic (high prices leading to demand destruction) spreading to other areas of consumer demand is especially elevated because goods consumption is already so far above trend—<b>in other words, high prices are that much more of a deterrent given households have already overconsumed in many areas.\"</b></p><p><blockquote>威尔逊的最后一个悲观观点是，企业已经达到了将不断上涨的投入成本转嫁给消费者的极限。正如他所说，虽然“我们采访的许多投资者对企业通过定价转嫁成本和保护利润率的能力持乐观态度”，但他会警告说，“几个消费终端市场的价格已经处于抑制需求的水平。我们认为，这种动态（高价格导致需求破坏）蔓延到其他消费需求领域的风险尤其高，因为商品消费已经远远高于趋势——<b>换句话说，考虑到许多地区的家庭已经过度消费，高价格更具威慑力。”</b></blockquote></p><p> <img src=\"https://static.tigerbbs.com/216bbe5eae73445b35a9152e741dccef\" tg-width=\"1009\" tg-height=\"801\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Translation: absent another multi-trillion stimmy - and thanks to the chaos in the democratic party we know one is unlikely to come - Wilson's call for a 20% drop in stocks in the next few months remains intact.</p><p><blockquote>翻译：如果没有另一场数万亿的骚动——由于民主党内部的混乱，我们知道不太可能发生——威尔逊关于未来几个月股市下跌 20% 的看涨期权仍然完好无损。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zerohedge.com/markets/morgan-stanley-dismisses-strong-rebound-remains-bearish-coming-earnings-disappointment\">zerohedge</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.zerohedge.com/markets/morgan-stanley-dismisses-strong-rebound-remains-bearish-coming-earnings-disappointment","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166571782","content_text":"For just a few hours last Monday, Morgan Stanley's chief economist felt vindicated: with stocks tumbling on Evergrande default fears, Wilson emerged from his faux-bull cocoon (havingraised his year-end S&P price target from 3,900 to 4,000 in Augustin a note that reeked of disgust with what he was being told to do) and warned that an \"Ice is coming\", referring to a 20% drop in stocks as opposed to the more modest 10% correction envisioned in his \"fire\" scenario, saying that \"the \"ice\" scenario is starting to look more likely, and could result in a more destructive outcome – i.e. a 20%+ correction\", a drop he expects will take place some time this fall.\nWilson also predicted that with earnings growth and PMIs set to drop, it would adversely impact forward PE multiples and by extension the S&P.\n\nWell, what a difference 7 days makes: with Evergrande default fears now long forgotten with little to no offshore contagion, the S&P is almost 150 points from its \"Evergrande Monday\" lows and once again pushing back toward all time highs (even if with a major rotation in the leadership as tech stocks are now sliding, having been replaced by value, cyclical and reopening names) in the process yet again foiling Wilson's bearish visions.\nSo has the market's sharp post-opex bounce changed the mind of the chief strategist that this seemingly invincible market will never go down again more than just a token 5% move?\nToday we got the answer in Wilson's latest weekly warm-up not, in which he makes it clear that his bearish outlook remains, and as he explains, \"our process tells us the risk-reward remains unattractive at the index level given slowing growth and rising rates. Meanwhile, price action can be interpreted bullishly or bearishly. With 3Q earnings season likely to bring a much more muted outcome, we remain defensive in our positioning.\"\nWe'll get to why in a second, but first Wilson - realizing that he would get a criticism for what many viewed as a premature victory lap - spends the first few paragraphs of his latest note going over the details of his analytical process. This is how he lays it out:\n\nOur equity strategy process has several key components. Most importantly, we focus on the fundamentals of growth and valuation to determine whether the overall market is attractive and which sectors and stocks look the best/worst.The rate of change on growth is more important than the absolute level, and we use a market-based equity risk premium framework that works well as long as you apply the correct regime when using it. In that regard, we’re an avid student of market cycles and believe historical analogs can be helpful. For example, the mid cycle transition narrative that has worked so well this year is derived directly from our study of historical economic and market cycles.\n\n\nThe final component we spend a lot of time on is price.While most would call this technical analysis, we’d like to think we do it a little bit differently. Markets aren’t always efficient, but we believe they are often very good leading indicators for the fundamentals—the ultimate driver of value. This is especially true if one looks at the internal movements and relative strength of individual securities. In short, \n we find these internals to be much more helpful than simply looking at the major averages.\n\n\nThis year, we think the process has lived up to its promise quite well with the price action lining up nicely with the fundamental backdrop.In short, the large cap quality leadership since March is signaling what we believe is about to happen—i.e., decelerating growth and tightening financial conditions. The question for investors is whether the price action has fully discounted those outcomes.\n\nWith that disclosure in hand, and with the clear understanding that at least in his view investors are not discounting any adverse outcomes at this point, Wilson proceeds to discuss the recent market action, noting that stocks\"sold off hard last Monday on concerns about the Evergrande bankruptcy\"and while he adds that it is the Morgan Stanley \"house view\" that it likely won’t lead to a major financial contagion, \"it will probably weigh on China growth for the next few quarters which means that the growth deceleration we are expecting could be a bit worse.\"\nThe other reason Wilson suggests was behind the market weakness early last week \"likely had to do with concern about the Fed articulating its plans to taper asset purchases later this year and perhaps even move up the timing of rate hikes to next year. On that score, the Fed did not disappoint as they pretty much told us to expect the taper to begin in December.The surprise was the speed in which they expect to be done tapering—by mid 2022.This is about a quarter sooner than the market had been anticipating and does move up the odds for a rate hike in 2022.\"\nCuriously last week's rally happened in the aftermath of the market's perplexing kneejerk response to the Fed meeting on Wednesday, when stocks rallied even as bonds sold off sharply, particularly at the back end. Real 10-year yields were up 11bps in 2 days and are now up 31bps in just 8 weeks (Exhibit 1). That according to Wilson is \"tightening of financial conditions for sure\" and should weigh on PEs overall but it also has big implications for what should work at the sector/style level (Exhibit 2).\n\nIn short, Wilson digs in and claims that higher real rates should mean lower P/Es overall which likely means lower S&P 500, thus validating his bearish view which still sees the S&P dropping some 20% from its current perch to hit 4,000 by year end. However, he concedes, \"it may also mean value over growth and small caps over Nasdaq even as the overall equity market goes lower.\"\nWhich brings us to the key question we spent quite some time discussing last week, namelywhy did stocks rally so much into the end of the weekon what Wilson says are odds that growth will decelerate more than expected from Evergrande and financial conditions may tighten faster?\nHere Wilson is at least honest - as he puts it - and says \"we’re not sure but we think this may be a time when the markets are playing tricks on investors and even setting a bit of a trap.\" Actually it's simpler than that and has to do with thegamma reversal and technical flows we pointed out last week, but one has to be a \"greek geek\" - like Nomura's Charlie McElligott - to get that.\nThe other explanation proposed by Wilson is \"that investors were somewhat positioned for bad news going into the Fed meeting and the actual event simply served as a relief that it didn’t lead lower prices. This price action drove many investors to chase on Thursday for fear of missing out.In short, don’t underestimate the power of price to determine how investors interpret the facts.Just like negative price action can get people to sell the lows, positive price action can force people to buy\", he concludes.\nWhatever the reason for the initial bounce, it quickly accelerated and there was \"a lot of excitement last Thursday when stocks rallied sharply back above the 50 day moving average, a key barometer for many and a key level of support throughout this year for the S&P 500.\" That this happened when the 50DMA was broken \"on near record levels of volume in both the cash and derivatives markets\" only punctuated the strength of the rebound. By Friday, that moving average had been reclaimed and closed above it for the week, an important technical win as even Wilson admits. However, he then adds, from his vantage point, \"the very well defined uptrend that has been established over the past year was broken and not reclaimed. Instead, it looks like the rally from Wednesday to Friday was simply \"filling the gap\" created from Monday's break.\"\nHis conclusion on upcoming market action will hardly come as a surprise to those who have followed Wilson's progressive pessimism across 2021: pointing to the market's inability to recover its prior trendline, he says \"this leaves the technical picture very uncertain in our view and one can now break either way. With our fundamental view skewing poorly at the moment, we lean to the bearish outcome.\"\n\nGetting back to his process, Wilson then says that he has high conviction that \"earnings growth is likely to decelerate more than what the current consensus is forecasting.\" Furthermore, he thinks the market is starting to agree with that view and points to market breadth as a good leading indicator for earnings revision breadth where he says \"direction is clear\" and pointing to the newly shrinking market breadth, he reminds readers that earnings revision breadth is a good leading indicator for the overall market.\nIt will therefore hardly come as a surprise that with Wilson still clearly bearish, his advice to clients is \"don’t get too caught up in last week’s strong rebound from Monday’s sharp sell off\"which he views as a clean break of the uptrend and a filling of the gap created from Monday's crack. And with the technical picture murky, \"that's a time to trust the fundamental and cycle analyses which suggest lower equity prices ahead\"and as growth decelerates and financial conditions tighten, valuations are likely to fall from their lofty levels.\n* * *\nWith all that in mind, Wilson goes back to his core fundamental thesis which is simple: after a blockbuster Q2 season, earnings are set to drop substantially as a result of the margin compression we discussed most recently over the weekend, to wit:\n\nSince the second quarter of 2020 earnings results have come in much higher than consensus forecasts. Earnings beats ranged from 14% - 22% over this period while the median beat rate since 2008 is only 5%...We do not think companies will continue to beat at such an unprecedented rate and believe 3Q could see a material change in the more recent trend as supply chain issues and labor shortages pose a risk to both top line and margins.\n\n\n\n We looked at how 3Q earnings estimate revisions have trended at the industry group and sector level. Significant cuts have occurred in insurance, capital goods and transportation. \n Consumer Durables is the only area that has seen significant positive revisions at the industry group level. 3Q S&P 500 estimates have fallen by 77 bps over past 4 weeks. We expect more downside.\n\n\nNo surprises there, as the margin compression story is a familiar one (\"Margins Crushed As Producer Prices Explode At Record Pace In July\"). To Wilson, however, this is the story and one which the market refuses to even consider:\n2022 consensus margin estimates are historically lofty...we examine the risks to margins in coming quarters through two different top down approaches. The spread between GDP growth and wage growth correlates fairly closely with operating margins over time. Based on our economists' estimates, this spread should decelerate in coming quarters, which suggests margins should contract, not expand as bottom-up consensus expects.\n\nFurther, corporate transcript mentions of \"cost pressures\" and related terms are historically elevated. When this has happened in the past, margins have consolidated.\n\nWilson's final bearish point is that companies are reaching the limit on how much of rising input costs they can pass on to consumers. As he puts it, while \"many investors that we speak to are optimistic about corporates' ability to pass on cost through pricing and protect margins\" he would caution that \"prices in several consumer end markets are already at a level that is inhibiting demand. We think the risk of this dynamic (high prices leading to demand destruction) spreading to other areas of consumer demand is especially elevated because goods consumption is already so far above trend—in other words, high prices are that much more of a deterrent given households have already overconsumed in many areas.\"\n\nTranslation: absent another multi-trillion stimmy - and thanks to the chaos in the democratic party we know one is unlikely to come - Wilson's call for a 20% drop in stocks in the next few months remains intact.","news_type":1,"symbols_score_info":{".IXIC":0.9,".DJI":0.9,".SPX":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":3268,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":883740875,"gmtCreate":1631276713897,"gmtModify":1631892155839,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"10 to 15% good for buy the dip","listText":"10 to 15% good for buy the dip","text":"10 to 15% good for buy the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/883740875","repostId":"2166897344","repostType":4,"isVote":1,"tweetType":1,"viewCount":2662,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835854435,"gmtCreate":1629706484927,"gmtModify":1631892155842,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"BRK &amp; SE .... the least also 10% return pa ....&nbsp;long term holding&nbsp; ..[美金]&nbsp;[美金]&nbsp;","listText":"BRK &amp; SE .... the least also 10% return pa ....&nbsp;long term holding&nbsp; ..[美金]&nbsp;[美金]&nbsp;","text":"BRK & SE .... the least also 10% return pa .... long term holding ..[美金] [美金]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/835854435","repostId":"2161742695","repostType":4,"isVote":1,"tweetType":1,"viewCount":3861,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":831038307,"gmtCreate":1629271652709,"gmtModify":1631885409381,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Tepper sell mostly FAANG counter and adding Uber ..... holding cash or&nbsp;expecting buy in dip!","listText":"Tepper sell mostly FAANG counter and adding Uber ..... holding cash or&nbsp;expecting buy in dip!","text":"Tepper sell mostly FAANG counter and adding Uber ..... holding cash or expecting buy in dip!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/831038307","repostId":"1137059057","repostType":4,"isVote":1,"tweetType":1,"viewCount":3918,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898668126,"gmtCreate":1628494048065,"gmtModify":1631892155844,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Too big to move exponentially...this will be long term investment","listText":"Too big to move exponentially...this will be long term investment","text":"Too big to move exponentially...this will be long term investment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/898668126","repostId":"2157492988","repostType":4,"isVote":1,"tweetType":1,"viewCount":3213,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807727668,"gmtCreate":1628060748754,"gmtModify":1631892155849,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Vaccine follow by booster.... then booster combine w flu med ...how many vaccine a human need!","listText":"Vaccine follow by booster.... then booster combine w flu med ...how many vaccine a human need!","text":"Vaccine follow by booster.... then booster combine w flu med ...how many vaccine a human need!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807727668","repostId":"1124757232","repostType":4,"repost":{"id":"1124757232","kind":"news","pubTimestamp":1628045612,"share":"https://www.laohunote.com/m/news/1124757232?lang=zh_CN&edition=full","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical 和 Novavax 的股票在 2021 年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul>  <li>Pfizer might surprise to the upside.</li>  <li>Inari Medical is growing like gangbusters.</li>  <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞公司可能会感到惊讶。</li><li>Inari Medical 正在像破坏者一样成长。</li><li>随着 COVID-19 病毒的变异，Novavax 的疫苗可能是一种重要的加强注射。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待着正常化。但COVID正在变异，新德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>一个由 Motley Fool 撰稿人组成的小组为医疗保健股提供了三个想法，即使 COVID 情况变得更糟，这些股票也将在 2021 年上涨。阅读更多内容，了解为什么您可能想要购买股票<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">稻荷医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;-- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更大的运行空间</b></h3><b>乔治·布德威尔</b> <b>（辉瑞）：</b>美国制药巨头辉瑞在目前的新冠疫苗参与者中听起来可能不是一个性感的选择。华尔街目前的共识是制药商的疫苗 Comirnaty——与<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>-- 从 2022 年开始，从销售角度来看，势头将会减弱。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty 的商业寿命可能会比最初预期的长得多。虽然高度传播变种的出现对整个社会来说显然是一个可怕的消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company&nbsp;announced&nbsp;that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因 delta 问题而走高。首先也是最重要的，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。第二，辉瑞计划本月开始针对delta特异性版本的疫苗进行临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品和药物管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞公司已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株病毒的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对投资者来说，大局是辉瑞 2022 年的收入可能比 2021 年增长多达 9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了 delta 特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比 2021 年下降 14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a&nbsp;dividend-paying&nbsp;big pharma stock.</p><p><blockquote>辉瑞的股票可能会走向何方？从保守的角度来看，如果疫苗方面的所有因素都到位，股价应该达到 50 美元。这比该制药商的股价目前上涨了约 17%，这甚至还没有考虑到该公司目前水平下诱人的 3.64% 股息收益率。简而言之，如果这种情况发生，辉瑞的股票交易价格将仅为 2022 年销售额的 3.5 倍左右，这对于支付股息的大型制药股来说是一个相当温和的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b>&nbsp;<b>(Inari Medical):</b>&nbsp;If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to&nbsp;<i>The New York Times</i>&nbsp;-- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>稻荷医疗：销售额飙升</b></h3><b>帕特里克·巴富马</b> <b>（稻荷医疗）：</b>如果您正在寻找一只在疫情的顺风消退后具有持久动力的股票，请关注 Inari Medical。根据数据，2021 年 7 月 27 日新增 108,000 例新冠病例，为 2021 年 2 月 5 日以来最多<i>纽约时报</i>-- 这个数字是 7 月初七天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者致残和潜在威胁生命的血栓风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否可以完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021,&nbsp;up 130% from the same quarter last year&nbsp;and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在去除大血栓，而不需要强效的血栓破除药物。通过使用其ClotTriever和FlowTriever设备，Inari迄今已治疗了超过25,000名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500例手术，比去年同期增长130%，比2020年第四季度高出约20%。根据数据，截至 7 月 27 日，约 12% 的入院 COVID 患者出现血栓，美国约有 35,000 名 COVID 住院病人（并且还在增加）<i>泰晤士报</i>Inari 可能会看到符合条件的案件数量有所增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的成果非常惊人：</blockquote></p><p> <ul>  <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li>  <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li>  <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li>  <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>肺部中高危血栓的历史30天死亡率为9.7%，Inari 0.4%的30天死亡率令人印象深刻。</li><li>与常规护理的24.4%相比，30天再入院率下降了6.7%。</li><li>48小时内发生重大不良事件的发生率仅为1.3%。</li><li>手术后不需要在ICU住院。</li></ul>把所有这些加起来，Inari的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and&nbsp;18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，Inari 的市销率为 18，使其成为待售的成长型股票。</blockquote></p><p> Inari has&nbsp;less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari 在价值 38 亿美元的美国市场的渗透率不到 5%，而且在今年早些时候推出的欧洲也有很大的增长空间。这意味着这家市值 45 亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性手术，但它显然没有减缓Inari的速度，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b>&nbsp;<b>(Novavax):</b>&nbsp;The vaccine&nbsp;biotech&nbsp;Novavax had an amazing 2020, with its share price running up&nbsp;2,700%&nbsp;on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能升到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司 Novavax 在 2020 年表现出色，由于对其 COVID 疫苗的乐观情绪，其股价上涨了 2,700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股上涨了60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19 疫苗的积极第三阶段数据导致该股在年初飙升，但由于该公司将疫苗推向市场出现延误，股价已回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同制造设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管有这些延迟，长期投资者仍有理由看涨。制造业正在扩大规模，预计到第三季度末产量将达到每月 1 亿剂，到 12 月产量将达到每月 1.5 亿剂。虽然美国许多人已经接种了疫苗，但世界其他地区的机会是巨大的。Novavax 已向 COVAX（国际疫苗财团）预售了 11 亿剂疫苗，并已签约在全球供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a&nbsp;booster shot&nbsp;for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told&nbsp;<i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用作已经接种疫苗的人的加强注射。F.D.A. 代理首席科学家卢西亚娜·博里奥 (Luciana Borio) 博士表示：“它们可能确实是加强剂的合适选择。”2015年至2017年，被告知<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax 计划将其 COVID 疫苗与流感疫苗结合起来，形成一次性注射方案。虽然COVID的变异速度不如流感快，但在过去的一年里，我们已经看到了几种变异菌株。在未来几年，我们很可能需要接种不止一次疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-08-04 10:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical 和 Novavax 的股票在 2021 年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul>  <li>Pfizer might surprise to the upside.</li>  <li>Inari Medical is growing like gangbusters.</li>  <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞公司可能会感到惊讶。</li><li>Inari Medical 正在像破坏者一样成长。</li><li>随着 COVID-19 病毒的变异，Novavax 的疫苗可能是一种重要的加强注射。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待着正常化。但COVID正在变异，新德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>一个由 Motley Fool 撰稿人组成的小组为医疗保健股提供了三个想法，即使 COVID 情况变得更糟，这些股票也将在 2021 年上涨。阅读更多内容，了解为什么您可能想要购买股票<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">稻荷医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;-- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更大的运行空间</b></h3><b>乔治·布德威尔</b> <b>（辉瑞）：</b>美国制药巨头辉瑞在目前的新冠疫苗参与者中听起来可能不是一个性感的选择。华尔街目前的共识是制药商的疫苗 Comirnaty——与<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>-- 从 2022 年开始，从销售角度来看，势头将会减弱。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty 的商业寿命可能会比最初预期的长得多。虽然高度传播变种的出现对整个社会来说显然是一个可怕的消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company&nbsp;announced&nbsp;that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因 delta 问题而走高。首先也是最重要的，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。第二，辉瑞计划本月开始针对delta特异性版本的疫苗进行临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品和药物管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞公司已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株病毒的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对投资者来说，大局是辉瑞 2022 年的收入可能比 2021 年增长多达 9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了 delta 特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比 2021 年下降 14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a&nbsp;dividend-paying&nbsp;big pharma stock.</p><p><blockquote>辉瑞的股票可能会走向何方？从保守的角度来看，如果疫苗方面的所有因素都到位，股价应该达到 50 美元。这比该制药商的股价目前上涨了约 17%，这甚至还没有考虑到该公司目前水平下诱人的 3.64% 股息收益率。简而言之，如果这种情况发生，辉瑞的股票交易价格将仅为 2022 年销售额的 3.5 倍左右，这对于支付股息的大型制药股来说是一个相当温和的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b>&nbsp;<b>(Inari Medical):</b>&nbsp;If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to&nbsp;<i>The New York Times</i>&nbsp;-- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>稻荷医疗：销售额飙升</b></h3><b>帕特里克·巴富马</b> <b>（稻荷医疗）：</b>如果您正在寻找一只在疫情的顺风消退后具有持久动力的股票，请关注 Inari Medical。根据数据，2021 年 7 月 27 日新增 108,000 例新冠病例，为 2021 年 2 月 5 日以来最多<i>纽约时报</i>-- 这个数字是 7 月初七天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者致残和潜在威胁生命的血栓风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否可以完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021,&nbsp;up 130% from the same quarter last year&nbsp;and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在去除大血栓，而不需要强效的血栓破除药物。通过使用其ClotTriever和FlowTriever设备，Inari迄今已治疗了超过25,000名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500例手术，比去年同期增长130%，比2020年第四季度高出约20%。根据数据，截至 7 月 27 日，约 12% 的入院 COVID 患者出现血栓，美国约有 35,000 名 COVID 住院病人（并且还在增加）<i>泰晤士报</i>Inari 可能会看到符合条件的案件数量有所增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的成果非常惊人：</blockquote></p><p> <ul>  <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li>  <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li>  <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li>  <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>肺部中高危血栓的历史30天死亡率为9.7%，Inari 0.4%的30天死亡率令人印象深刻。</li><li>与常规护理的24.4%相比，30天再入院率下降了6.7%。</li><li>48小时内发生重大不良事件的发生率仅为1.3%。</li><li>手术后不需要在ICU住院。</li></ul>把所有这些加起来，Inari的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and&nbsp;18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，Inari 的市销率为 18，使其成为待售的成长型股票。</blockquote></p><p> Inari has&nbsp;less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari 在价值 38 亿美元的美国市场的渗透率不到 5%，而且在今年早些时候推出的欧洲也有很大的增长空间。这意味着这家市值 45 亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性手术，但它显然没有减缓Inari的速度，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b>&nbsp;<b>(Novavax):</b>&nbsp;The vaccine&nbsp;biotech&nbsp;Novavax had an amazing 2020, with its share price running up&nbsp;2,700%&nbsp;on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能升到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司 Novavax 在 2020 年表现出色，由于对其 COVID 疫苗的乐观情绪，其股价上涨了 2,700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股上涨了60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19 疫苗的积极第三阶段数据导致该股在年初飙升，但由于该公司将疫苗推向市场出现延误，股价已回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同制造设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管有这些延迟，长期投资者仍有理由看涨。制造业正在扩大规模，预计到第三季度末产量将达到每月 1 亿剂，到 12 月产量将达到每月 1.5 亿剂。虽然美国许多人已经接种了疫苗，但世界其他地区的机会是巨大的。Novavax 已向 COVAX（国际疫苗财团）预售了 11 亿剂疫苗，并已签约在全球供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a&nbsp;booster shot&nbsp;for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told&nbsp;<i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用作已经接种疫苗的人的加强注射。F.D.A. 代理首席科学家卢西亚娜·博里奥 (Luciana Borio) 博士表示：“它们可能确实是加强剂的合适选择。”2015年至2017年，被告知<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax 计划将其 COVID 疫苗与流感疫苗结合起来，形成一次性注射方案。虽然COVID的变异速度不如流感快，但在过去的一年里，我们已经看到了几种变异菌株。在未来几年，我们很可能需要接种不止一次疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"NARI":0.9}},"isVote":1,"tweetType":1,"viewCount":2549,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804003687,"gmtCreate":1627910827749,"gmtModify":1631892155851,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Don't under estimate the power of Delta","listText":"Don't under estimate the power of Delta","text":"Don't under estimate the power of Delta","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804003687","repostId":"1191539307","repostType":4,"isVote":1,"tweetType":1,"viewCount":1122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808039979,"gmtCreate":1627541757591,"gmtModify":1631892155854,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"With herd immunity and movement allowed, screen time will be reduce..everyone is looking forward to step out","listText":"With herd immunity and movement allowed, screen time will be reduce..everyone is looking forward to step out","text":"With herd immunity and movement allowed, screen time will be reduce..everyone is looking forward to step out","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/808039979","repostId":"2154927641","repostType":4,"isVote":1,"tweetType":1,"viewCount":802,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803779278,"gmtCreate":1627468387294,"gmtModify":1631892155858,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Stable and not drag by Broad Market&nbsp;","listText":"Stable and not drag by Broad Market&nbsp;","text":"Stable and not drag by Broad Market","images":[{"img":"https://static.tigerbbs.com/c7732bff46f8f82e6da946a8864266f3","width":"1080","height":"3778"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/803779278","isVote":1,"tweetType":1,"viewCount":832,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":177421549,"gmtCreate":1627258407481,"gmtModify":1631892155863,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"6 out of 17 is biopharma/medical related... tailwind of&nbsp;covid!","listText":"6 out of 17 is biopharma/medical related... tailwind of&nbsp;covid!","text":"6 out of 17 is biopharma/medical related... tailwind of covid!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/177421549","repostId":"1118041582","repostType":4,"repost":{"id":"1118041582","kind":"news","pubTimestamp":1627175995,"share":"https://www.laohunote.com/m/news/1118041582?lang=zh_CN&edition=full","pubTime":"2021-07-25 09:19","market":"us","language":"en","title":"US IPO Week Ahead: 17 IPOs are coming<blockquote>美国 IPO 未来一周：17 家 IPO 即将到来</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118041582","media":"Renaissance Capital","summary":"After another week of record activity, the IPO market is expected to remain hot with 17 IPOs schedul","content":"<p>After another week of record activity, the IPO market is expected to remain hot with 17 IPOs scheduled for the week ahead.</p><p><blockquote>经过又一周创纪录的活动，IPO市场预计将保持火爆，未来一周将有17起IPO。</blockquote></p><p> Long-awaited retail brokerage&nbsp;<b>Robinhood Markets</b>(HOOD) plans to raise $2.2 billion at a $36.8 billion market cap. The company offers a no-commission retail brokerage platform with over 18 million MAUs. Despite triple-digit revenue growth in the 1Q21, the platform is dependent on trading volumes, and the recent retail trading boom may be unsustainable.</p><p><blockquote>期待已久的零售经纪业务<b>罗宾汉市场</b>（HOOD）计划以368亿美元的市值筹集22亿美元。该公司提供一个免佣金的零售经纪平台，拥有超过1800万MAU。尽管2021年第一季度的收入实现了三位数的增长，但该平台依赖于交易量，最近的零售交易热潮可能是不可持续的。</blockquote></p><p> Vehicle battery maker&nbsp;<b>Clarios International</b>(BTRY) plans to raise $1.7 billion at a $9.7 billion market cap. The company manufactures low-voltage vehicles batteries globally, stating that it has the number one market position in the Americas and EMEA. Profitable on an EBIT basis, Clarios saw revenue growth accelerate in the 1H FY21 after turning negative in the FY20 due to COVID.</p><p><blockquote>汽车电池制造商<b>克拉里奥斯国际</b>(BTRY) 计划以 97 亿美元的市值筹集 17 亿美元。该公司在全球范围内生产低压汽车电池，并表示其在美洲和欧洲、中东和非洲地区拥有第一大市场地位。按息税前利润计算，Clarios 在 2020 财年因新冠疫情而出现负增长后，在 2021 财年上半年收入增长加速。</blockquote></p><p> Altice’s ad-tech platform&nbsp;<b>Teads</b>(TEAD) plans to raise $751 million at a $4.6 billion market cap. Teads operates a cloud-based programmatic digital advertising platform for advertisers and publishers. Profitable with solid growth, Teads provides monetization services to about 3,100 publishers.</p><p><blockquote>Altice的广告技术平台<b>提德</b>(TEAD) 计划以 46 亿美元的市值筹集 7.51 亿美元。Teads为广告商和出版商运营一个基于云的程序化数字广告平台。Teads 盈利稳健，为约 3,100 家出版商提供货币化服务。</blockquote></p><p> Education software provider&nbsp;<b>PowerSchool Holdings</b>(PWSC) plans to raise $750 million at a $3.7 billion market cap. The company provides an education platform for teachers to manage classroom activities such as collecting work and grading assignments. Serving over 12,000 customers in over 90 countries globally, PowerSchool turned profitable on a net income basis in the 1Q21.</p><p><blockquote>教育软件提供商<b>PowerSchool控股</b>（PWSC）计划以37亿美元的市值筹集7.5亿美元。该公司为教师提供了一个教育平台，用于管理课堂活动，如收集作业和批改作业。PowerSchool为全球90多个国家的12,000多名客户提供服务，在2021年第一季度实现了净利润盈利。</blockquote></p><p> After withdrawing its IPO attempt in 2018,<b>Dole</b>(DOLE) plans to raise $559 million at a $2.0 billion market cap. This leading fruit and vegetable company offers over 300 products sourced from over 30 countries to over 80 countries globally. Slow growing and profitable, Dole's offering is being made in connection with its merger with Total Produce.</p><p><blockquote>在2018年撤回IPO尝试后，<b>下</b>（都乐）计划以 20 亿美元的市值筹集 5.59 亿美元。这家领先的水果和蔬菜公司提供来自全球30多个国家和80多个国家的300多种产品。都乐的发行增长缓慢且盈利，与其与道达尔农产品合并有关。</blockquote></p><p> Language learning platform&nbsp;<b>Duolingo</b>(DUOL) plans to raise $460 million at a $4.1 billion market cap. Duolingo provides an online platform for over 300 million users to learn over 30 new languages. Benefiting from a COVID-related boost in demand, Duolingo posted triple-digit growth in 2020.</p><p><blockquote>语言学习平台<b>多邻国</b>(DUOL) 计划以 41 亿美元的市值筹集 4.6 亿美元。多邻国为超过3亿用户提供了一个学习30多种新语言的在线平台。受益于新冠疫情相关的需求增长，多邻国在 2020 年实现了三位数的增长。</blockquote></p><p> <b>Traeger</b>(COOK) plans to raise $400 million at a $2.2 billion market cap. This company makes premium backyard wood pellet grills with a tech feature, allowing owners to program, monitor, and control their grill through the Traeger app. Traeger is a category leader of the wood pellet grill, growing revenue at a 28% CAGR from 2017 to 2020.</p><p><blockquote><b>携带者</b>（库克）计划以22亿美元的市值筹集4亿美元。这家公司生产具有技术功能的优质后院木质颗粒烤架，允许业主通过Traeger应用程序对他们的烤架进行编程、监控和控制。Traeger是木质颗粒烤架的类别领导者，从2017年到2020年，收入以28%的CAGR增长。</blockquote></p><p> Israeli anti-fraud firm&nbsp;<b>Riskified</b>(RSKD) plans to raise $333 million at a $3.1 billion market cap. This company provides e-commerce fraud protection for enterprises. Growing but unprofitable, Riskified saw its free cash flow swing positive in the 1Q21.</p><p><blockquote>以色列反欺诈公司<b>风险化</b>(RSKD) 计划以 31 亿美元的市值筹集 3.33 亿美元。这家公司为企业提供电子商务欺诈保护。Riskified 不断增长但无利可图，其自由现金流在2021年第一季度中呈正波动。</blockquote></p><p> Financial software provider&nbsp;<b>MeridianLink</b>(MLNK) plans to raise $300 million at a $2.1 billion market cap. MeridianLink offers a cloud-based digital lending and account opening platform for mid-market community banks and credit unions. Although business is cyclical, the company saw double-digit organic growth in the FY20 due to strong mortgage activity.</p><p><blockquote>财务软件提供商<b>子午线</b>(MLNK) 计划以 21 亿美元的市值筹集 3 亿美元。MeridianLink为中端市场社区银行和信用合作社提供基于云的数字贷款和开户平台。尽管业务具有周期性，但由于强劲的抵押贷款活动，该公司在 2020 财年实现了两位数的有机增长。</blockquote></p><p> Smart home integration system&nbsp;<b>Snap One Holdings</b>(SNPO) plans to raise $270 million at a $1.5 billion market cap. This company provides smart home technology products to over 16,000 professional integrators. Snap One has demonstrated solid growth and was profitable on an EBIT basis in the 1Q21.</p><p><blockquote>智能家居集成系统<b>Snap一号控股</b>(SNPO) 计划以 15 亿美元的市值筹集 2.7 亿美元。这家公司为超过16,000家专业集成商提供智能家居技术产品。Snap一号表现出稳健的增长，并在 2021 年第一季度按息税前利润计算实现盈利。</blockquote></p><p> Specialty funding solutions provider&nbsp;<b>Preston Hollow Community Capital</b>(PHCC) plans to raise $200 million at a $2.3 billion market cap. This company is a market leader in providing specialized impact financing solutions for projects of significant social and economic importance to local communities in the US. It serves a variety of areas, including infrastructure, education, healthcare, and housing.</p><p><blockquote>专业融资解决方案提供商<b>普雷斯顿霍洛社区资本</b>(PHCC) 计划以 23 亿美元的市值筹集 2 亿美元。该公司是为对美国当地社区具有重大社会和经济重要性的项目提供专业影响力融资解决方案的市场领导者。它服务于多个领域，包括基础设施、教育、医疗保健和住房。</blockquote></p><p> Vaccine biotech&nbsp;<b>Icosavax</b>(ICVX) plans to raise $150 million at a $590 million market cap. This clinical stage biotech is initially focused on developing vaccines against infectious respiratory diseases using its virus-like particle platform technology. Its most advanced candidate is currently in a Phase 1/2 trial for SARS-CoV-2.</p><p><blockquote>疫苗生物技术<b>伊科萨瓦克斯</b>(ICVX) 计划以 5.9 亿美元的市值筹集 1.5 亿美元。这家临床阶段的生物技术公司最初专注于使用其类似病毒的颗粒平台技术开发针对传染性呼吸道疾病的疫苗。其最先进的候选药物目前正处于新型冠状病毒的1/2期试验中。</blockquote></p><p> Cancer biotech&nbsp;<b>Candel Therapeutics</b>(CADL) plans to raise $85 million at a $398 million market cap. Candel's most advanced candidate is currently in a Phase 3 trial in combination with prodrug valacyclovir for newly diagnosed localized prostate cancer with an intermediate or high-risk for progression. The company expects to complete enrollment in the 3Q21 with a final data readout in 2024.</p><p><blockquote>癌症生物技术<b>坎德尔疗法</b>（CADL）计划以3.98亿美元的市值筹集8500万美元。Candel 最先进的候选药物目前正在与前药伐昔洛韦联合进行 3 期试验，用于治疗新诊断的局限性前列腺癌，具有中等或高风险进展。该公司预计将于 2024 年完成2021年第三季度的注册，并公布最终数据。</blockquote></p><p></p><p> Rare disease biotech&nbsp;<b>Rallybio</b>(RLYB) plans to raise $81 million at a $465 million market cap. This clinical stage biotech is developing antibody therapies for rare diseases. Its lead program is currently being evaluated to treat fetal and neonatal alloimmune thrombocytopenia in a Phase 1/2 trial.</p><p><blockquote>罕见病生物技术<b>拉力赛生物</b>（RLYB）计划以4.65亿美元的市值筹集8100万美元。这家临床阶段的生物技术公司正在开发针对罕见疾病的抗体疗法。目前正在评估其 lead 项目，以在 1/2 期试验中治疗胎儿和新生儿同种免疫性血小板减少症。</blockquote></p><p> <b>Ocean Biomedical</b>(OCEA) plans to raise $50 million at a $506 million market cap. The company is currently pursuing preclinical programs in oncology, fibrosis, infectious disease, and inflammation that have been licensed directly or indirectly from Brown University, Stanford University, and Rhode Island Hospital.</p><p><blockquote><b>海洋生物医学</b>（OCEA）计划以5.06亿美元的市值筹集5000万美元。该公司目前正在开展肿瘤学、纤维化、传染病和炎症方面的临床前项目，这些项目已获得布朗大学、斯坦福大学和罗德岛医院的直接或间接许可。</blockquote></p><p> After postponing in November 2020,<b>IN8bio</b>(INAB) plans to raise $44 million at a $215 million market cap. This Phase 1 biotech is developing allogeneic gamma-delta T cell therapies to treat solid tumors. Although gamma-delta T cells could potentially treat solid tumors, the company is very early stage and has dosed a limited number of patients.</p><p><blockquote>2020年11月延期后，<b>因8生物</b>（INAB）计划以2.15亿美元的市值筹集4400万美元。这家一期生物技术公司正在开发同种异体γ-δ T细胞疗法来治疗实体瘤。尽管 gamma-delta T 细胞有可能治疗实体瘤，但该公司仍处于非常早期的阶段，并且已为有限数量的患者注射了剂量。</blockquote></p><p> Female cancer biotech&nbsp;<b>Context Therapeutics</b>(CNTX) plans to raise $20 million at a $93 million market cap. Context is developing treatments for female cancers, such as breast, ovarian, and endometrial cancer. The company’s lead candidate is currently in Phase 2 trials for ovarian and endometrial cancer, with preliminary results expected in the 2H21 and the 1H22.</p><p><blockquote>女性癌症生物技术<b>背景疗法</b>(CNTX) 计划以 9300 万美元的市值筹集 2000 万美元。Context 正在开发治疗女性癌症的方法，例如乳腺癌、卵巢癌和子宫内膜癌。该公司的主要候选药物目前正在进行卵巢癌和子宫内膜癌的 2 期试验，预计 2H21 和 1H22 将有初步结果。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4b38a8af5f92621b2633830553616b5d\" tg-width=\"1271\" tg-height=\"702\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/5faec597a337345b21c846808295821d\" tg-width=\"1272\" tg-height=\"676\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/021cc62ff4eaabd0b6a7dee91fc0d63e\" tg-width=\"1270\" tg-height=\"483\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>IPO Market Snapshot</b></p><p><blockquote><b>IPO市场快照</b></blockquote></p><p> The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/22/2021, the Renaissance IPO Index was down 1.0% year-to-date, while the S&amp;P 500 was up 16.3%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 3.0% year-to-date, while the ACWX was up 8.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include EQT Partners and Smoore International.</p><p><blockquote>文艺复兴IPO指数是新上市公司的市值加权篮子。截至2021年7月22日，文艺复兴IPO指数年初至今下跌1.0%，而标普500上涨16.3%。Renaissance Capital 的 IPO ETF（纽约证券交易所股票代码：IPO）追踪该指数，持有量最大的 ETF 包括 Snowflake (SNOW) 和 Palantir Technologies (PLTR)。Renaissance International IPO 指数今年迄今下跌 3.0%，而 ACWX 指数上涨 8.1%。Renaissance Capital 的国际 IPO ETF（纽约证券交易所股票代码：IPOS）追踪该指数，持有的 ETF 包括 EQT Partners 和 Smoore International。</blockquote></p><p></p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: 17 IPOs are coming<blockquote>美国 IPO 未来一周：17 家 IPO 即将到来</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: 17 IPOs are coming<blockquote>美国 IPO 未来一周：17 家 IPO 即将到来</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Renaissance Capital</strong><span class=\"h-time small\">2021-07-25 09:19</span>\n</p>\n</h4>\n</header>\n<article>\n<p>After another week of record activity, the IPO market is expected to remain hot with 17 IPOs scheduled for the week ahead.</p><p><blockquote>经过又一周创纪录的活动，IPO市场预计将保持火爆，未来一周将有17起IPO。</blockquote></p><p> Long-awaited retail brokerage&nbsp;<b>Robinhood Markets</b>(HOOD) plans to raise $2.2 billion at a $36.8 billion market cap. The company offers a no-commission retail brokerage platform with over 18 million MAUs. Despite triple-digit revenue growth in the 1Q21, the platform is dependent on trading volumes, and the recent retail trading boom may be unsustainable.</p><p><blockquote>期待已久的零售经纪业务<b>罗宾汉市场</b>（HOOD）计划以368亿美元的市值筹集22亿美元。该公司提供一个免佣金的零售经纪平台，拥有超过1800万MAU。尽管2021年第一季度的收入实现了三位数的增长，但该平台依赖于交易量，最近的零售交易热潮可能是不可持续的。</blockquote></p><p> Vehicle battery maker&nbsp;<b>Clarios International</b>(BTRY) plans to raise $1.7 billion at a $9.7 billion market cap. The company manufactures low-voltage vehicles batteries globally, stating that it has the number one market position in the Americas and EMEA. Profitable on an EBIT basis, Clarios saw revenue growth accelerate in the 1H FY21 after turning negative in the FY20 due to COVID.</p><p><blockquote>汽车电池制造商<b>克拉里奥斯国际</b>(BTRY) 计划以 97 亿美元的市值筹集 17 亿美元。该公司在全球范围内生产低压汽车电池，并表示其在美洲和欧洲、中东和非洲地区拥有第一大市场地位。按息税前利润计算，Clarios 在 2020 财年因新冠疫情而出现负增长后，在 2021 财年上半年收入增长加速。</blockquote></p><p> Altice’s ad-tech platform&nbsp;<b>Teads</b>(TEAD) plans to raise $751 million at a $4.6 billion market cap. Teads operates a cloud-based programmatic digital advertising platform for advertisers and publishers. Profitable with solid growth, Teads provides monetization services to about 3,100 publishers.</p><p><blockquote>Altice的广告技术平台<b>提德</b>(TEAD) 计划以 46 亿美元的市值筹集 7.51 亿美元。Teads为广告商和出版商运营一个基于云的程序化数字广告平台。Teads 盈利稳健，为约 3,100 家出版商提供货币化服务。</blockquote></p><p> Education software provider&nbsp;<b>PowerSchool Holdings</b>(PWSC) plans to raise $750 million at a $3.7 billion market cap. The company provides an education platform for teachers to manage classroom activities such as collecting work and grading assignments. Serving over 12,000 customers in over 90 countries globally, PowerSchool turned profitable on a net income basis in the 1Q21.</p><p><blockquote>教育软件提供商<b>PowerSchool控股</b>（PWSC）计划以37亿美元的市值筹集7.5亿美元。该公司为教师提供了一个教育平台，用于管理课堂活动，如收集作业和批改作业。PowerSchool为全球90多个国家的12,000多名客户提供服务，在2021年第一季度实现了净利润盈利。</blockquote></p><p> After withdrawing its IPO attempt in 2018,<b>Dole</b>(DOLE) plans to raise $559 million at a $2.0 billion market cap. This leading fruit and vegetable company offers over 300 products sourced from over 30 countries to over 80 countries globally. Slow growing and profitable, Dole's offering is being made in connection with its merger with Total Produce.</p><p><blockquote>在2018年撤回IPO尝试后，<b>下</b>（都乐）计划以 20 亿美元的市值筹集 5.59 亿美元。这家领先的水果和蔬菜公司提供来自全球30多个国家和80多个国家的300多种产品。都乐的发行增长缓慢且盈利，与其与道达尔农产品合并有关。</blockquote></p><p> Language learning platform&nbsp;<b>Duolingo</b>(DUOL) plans to raise $460 million at a $4.1 billion market cap. Duolingo provides an online platform for over 300 million users to learn over 30 new languages. Benefiting from a COVID-related boost in demand, Duolingo posted triple-digit growth in 2020.</p><p><blockquote>语言学习平台<b>多邻国</b>(DUOL) 计划以 41 亿美元的市值筹集 4.6 亿美元。多邻国为超过3亿用户提供了一个学习30多种新语言的在线平台。受益于新冠疫情相关的需求增长，多邻国在 2020 年实现了三位数的增长。</blockquote></p><p> <b>Traeger</b>(COOK) plans to raise $400 million at a $2.2 billion market cap. This company makes premium backyard wood pellet grills with a tech feature, allowing owners to program, monitor, and control their grill through the Traeger app. Traeger is a category leader of the wood pellet grill, growing revenue at a 28% CAGR from 2017 to 2020.</p><p><blockquote><b>携带者</b>（库克）计划以22亿美元的市值筹集4亿美元。这家公司生产具有技术功能的优质后院木质颗粒烤架，允许业主通过Traeger应用程序对他们的烤架进行编程、监控和控制。Traeger是木质颗粒烤架的类别领导者，从2017年到2020年，收入以28%的CAGR增长。</blockquote></p><p> Israeli anti-fraud firm&nbsp;<b>Riskified</b>(RSKD) plans to raise $333 million at a $3.1 billion market cap. This company provides e-commerce fraud protection for enterprises. Growing but unprofitable, Riskified saw its free cash flow swing positive in the 1Q21.</p><p><blockquote>以色列反欺诈公司<b>风险化</b>(RSKD) 计划以 31 亿美元的市值筹集 3.33 亿美元。这家公司为企业提供电子商务欺诈保护。Riskified 不断增长但无利可图，其自由现金流在2021年第一季度中呈正波动。</blockquote></p><p> Financial software provider&nbsp;<b>MeridianLink</b>(MLNK) plans to raise $300 million at a $2.1 billion market cap. MeridianLink offers a cloud-based digital lending and account opening platform for mid-market community banks and credit unions. Although business is cyclical, the company saw double-digit organic growth in the FY20 due to strong mortgage activity.</p><p><blockquote>财务软件提供商<b>子午线</b>(MLNK) 计划以 21 亿美元的市值筹集 3 亿美元。MeridianLink为中端市场社区银行和信用合作社提供基于云的数字贷款和开户平台。尽管业务具有周期性，但由于强劲的抵押贷款活动，该公司在 2020 财年实现了两位数的有机增长。</blockquote></p><p> Smart home integration system&nbsp;<b>Snap One Holdings</b>(SNPO) plans to raise $270 million at a $1.5 billion market cap. This company provides smart home technology products to over 16,000 professional integrators. Snap One has demonstrated solid growth and was profitable on an EBIT basis in the 1Q21.</p><p><blockquote>智能家居集成系统<b>Snap一号控股</b>(SNPO) 计划以 15 亿美元的市值筹集 2.7 亿美元。这家公司为超过16,000家专业集成商提供智能家居技术产品。Snap一号表现出稳健的增长，并在 2021 年第一季度按息税前利润计算实现盈利。</blockquote></p><p> Specialty funding solutions provider&nbsp;<b>Preston Hollow Community Capital</b>(PHCC) plans to raise $200 million at a $2.3 billion market cap. This company is a market leader in providing specialized impact financing solutions for projects of significant social and economic importance to local communities in the US. It serves a variety of areas, including infrastructure, education, healthcare, and housing.</p><p><blockquote>专业融资解决方案提供商<b>普雷斯顿霍洛社区资本</b>(PHCC) 计划以 23 亿美元的市值筹集 2 亿美元。该公司是为对美国当地社区具有重大社会和经济重要性的项目提供专业影响力融资解决方案的市场领导者。它服务于多个领域，包括基础设施、教育、医疗保健和住房。</blockquote></p><p> Vaccine biotech&nbsp;<b>Icosavax</b>(ICVX) plans to raise $150 million at a $590 million market cap. This clinical stage biotech is initially focused on developing vaccines against infectious respiratory diseases using its virus-like particle platform technology. Its most advanced candidate is currently in a Phase 1/2 trial for SARS-CoV-2.</p><p><blockquote>疫苗生物技术<b>伊科萨瓦克斯</b>(ICVX) 计划以 5.9 亿美元的市值筹集 1.5 亿美元。这家临床阶段的生物技术公司最初专注于使用其类似病毒的颗粒平台技术开发针对传染性呼吸道疾病的疫苗。其最先进的候选药物目前正处于新型冠状病毒的1/2期试验中。</blockquote></p><p> Cancer biotech&nbsp;<b>Candel Therapeutics</b>(CADL) plans to raise $85 million at a $398 million market cap. Candel's most advanced candidate is currently in a Phase 3 trial in combination with prodrug valacyclovir for newly diagnosed localized prostate cancer with an intermediate or high-risk for progression. The company expects to complete enrollment in the 3Q21 with a final data readout in 2024.</p><p><blockquote>癌症生物技术<b>坎德尔疗法</b>（CADL）计划以3.98亿美元的市值筹集8500万美元。Candel 最先进的候选药物目前正在与前药伐昔洛韦联合进行 3 期试验，用于治疗新诊断的局限性前列腺癌，具有中等或高风险进展。该公司预计将于 2024 年完成2021年第三季度的注册，并公布最终数据。</blockquote></p><p></p><p> Rare disease biotech&nbsp;<b>Rallybio</b>(RLYB) plans to raise $81 million at a $465 million market cap. This clinical stage biotech is developing antibody therapies for rare diseases. Its lead program is currently being evaluated to treat fetal and neonatal alloimmune thrombocytopenia in a Phase 1/2 trial.</p><p><blockquote>罕见病生物技术<b>拉力赛生物</b>（RLYB）计划以4.65亿美元的市值筹集8100万美元。这家临床阶段的生物技术公司正在开发针对罕见疾病的抗体疗法。目前正在评估其 lead 项目，以在 1/2 期试验中治疗胎儿和新生儿同种免疫性血小板减少症。</blockquote></p><p> <b>Ocean Biomedical</b>(OCEA) plans to raise $50 million at a $506 million market cap. The company is currently pursuing preclinical programs in oncology, fibrosis, infectious disease, and inflammation that have been licensed directly or indirectly from Brown University, Stanford University, and Rhode Island Hospital.</p><p><blockquote><b>海洋生物医学</b>（OCEA）计划以5.06亿美元的市值筹集5000万美元。该公司目前正在开展肿瘤学、纤维化、传染病和炎症方面的临床前项目，这些项目已获得布朗大学、斯坦福大学和罗德岛医院的直接或间接许可。</blockquote></p><p> After postponing in November 2020,<b>IN8bio</b>(INAB) plans to raise $44 million at a $215 million market cap. This Phase 1 biotech is developing allogeneic gamma-delta T cell therapies to treat solid tumors. Although gamma-delta T cells could potentially treat solid tumors, the company is very early stage and has dosed a limited number of patients.</p><p><blockquote>2020年11月延期后，<b>因8生物</b>（INAB）计划以2.15亿美元的市值筹集4400万美元。这家一期生物技术公司正在开发同种异体γ-δ T细胞疗法来治疗实体瘤。尽管 gamma-delta T 细胞有可能治疗实体瘤，但该公司仍处于非常早期的阶段，并且已为有限数量的患者注射了剂量。</blockquote></p><p> Female cancer biotech&nbsp;<b>Context Therapeutics</b>(CNTX) plans to raise $20 million at a $93 million market cap. Context is developing treatments for female cancers, such as breast, ovarian, and endometrial cancer. The company’s lead candidate is currently in Phase 2 trials for ovarian and endometrial cancer, with preliminary results expected in the 2H21 and the 1H22.</p><p><blockquote>女性癌症生物技术<b>背景疗法</b>(CNTX) 计划以 9300 万美元的市值筹集 2000 万美元。Context 正在开发治疗女性癌症的方法，例如乳腺癌、卵巢癌和子宫内膜癌。该公司的主要候选药物目前正在进行卵巢癌和子宫内膜癌的 2 期试验，预计 2H21 和 1H22 将有初步结果。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4b38a8af5f92621b2633830553616b5d\" tg-width=\"1271\" tg-height=\"702\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/5faec597a337345b21c846808295821d\" tg-width=\"1272\" tg-height=\"676\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/021cc62ff4eaabd0b6a7dee91fc0d63e\" tg-width=\"1270\" tg-height=\"483\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>IPO Market Snapshot</b></p><p><blockquote><b>IPO市场快照</b></blockquote></p><p> The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/22/2021, the Renaissance IPO Index was down 1.0% year-to-date, while the S&amp;P 500 was up 16.3%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 3.0% year-to-date, while the ACWX was up 8.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include EQT Partners and Smoore International.</p><p><blockquote>文艺复兴IPO指数是新上市公司的市值加权篮子。截至2021年7月22日，文艺复兴IPO指数年初至今下跌1.0%，而标普500上涨16.3%。Renaissance Capital 的 IPO ETF（纽约证券交易所股票代码：IPO）追踪该指数，持有量最大的 ETF 包括 Snowflake (SNOW) 和 Palantir Technologies (PLTR)。Renaissance International IPO 指数今年迄今下跌 3.0%，而 ACWX 指数上涨 8.1%。Renaissance Capital 的国际 IPO ETF（纽约证券交易所股票代码：IPOS）追踪该指数，持有的 ETF 包括 EQT Partners 和 Smoore International。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/84600/US-IPO-Week-Ahead-Robinhood%E2%80%99s-billion-dollar-deal-headlines-a-17-IPO-week\">Renaissance Capital</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DUOL":"多邻国","CADLF":"CADELER AS","SNPO":"Snap One Holdings Corp.","INAB":"IN8bio, Inc.","COOK":"Traeger Inc. (TGPX Holdings I LLC)",".SPX":"S&P 500 Index","HOOD":"Robinhood","DOLE":"都乐食品","MLNK":"MeridianLink, Inc. (ex-Project Angel Parent, LLC)",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","RSKD":"Riskified Ltd.","FEOVF":"Oceanic Iron Ore Corp.","TEAD":"Teads Holding","PWSC":"PowerSchool Holdings, Inc.","RLYB":"Rallybio Corp.","CNTX":"Context Therapeutics Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/84600/US-IPO-Week-Ahead-Robinhood%E2%80%99s-billion-dollar-deal-headlines-a-17-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118041582","content_text":"After another week of record activity, the IPO market is expected to remain hot with 17 IPOs scheduled for the week ahead.\nLong-awaited retail brokerage Robinhood Markets(HOOD) plans to raise $2.2 billion at a $36.8 billion market cap. The company offers a no-commission retail brokerage platform with over 18 million MAUs. Despite triple-digit revenue growth in the 1Q21, the platform is dependent on trading volumes, and the recent retail trading boom may be unsustainable.\nVehicle battery maker Clarios International(BTRY) plans to raise $1.7 billion at a $9.7 billion market cap. The company manufactures low-voltage vehicles batteries globally, stating that it has the number one market position in the Americas and EMEA. Profitable on an EBIT basis, Clarios saw revenue growth accelerate in the 1H FY21 after turning negative in the FY20 due to COVID.\nAltice’s ad-tech platform Teads(TEAD) plans to raise $751 million at a $4.6 billion market cap. Teads operates a cloud-based programmatic digital advertising platform for advertisers and publishers. Profitable with solid growth, Teads provides monetization services to about 3,100 publishers.\nEducation software provider PowerSchool Holdings(PWSC) plans to raise $750 million at a $3.7 billion market cap. The company provides an education platform for teachers to manage classroom activities such as collecting work and grading assignments. Serving over 12,000 customers in over 90 countries globally, PowerSchool turned profitable on a net income basis in the 1Q21.\nAfter withdrawing its IPO attempt in 2018,Dole(DOLE) plans to raise $559 million at a $2.0 billion market cap. This leading fruit and vegetable company offers over 300 products sourced from over 30 countries to over 80 countries globally. Slow growing and profitable, Dole's offering is being made in connection with its merger with Total Produce.\nLanguage learning platform Duolingo(DUOL) plans to raise $460 million at a $4.1 billion market cap. Duolingo provides an online platform for over 300 million users to learn over 30 new languages. Benefiting from a COVID-related boost in demand, Duolingo posted triple-digit growth in 2020.\nTraeger(COOK) plans to raise $400 million at a $2.2 billion market cap. This company makes premium backyard wood pellet grills with a tech feature, allowing owners to program, monitor, and control their grill through the Traeger app. Traeger is a category leader of the wood pellet grill, growing revenue at a 28% CAGR from 2017 to 2020.\nIsraeli anti-fraud firm Riskified(RSKD) plans to raise $333 million at a $3.1 billion market cap. This company provides e-commerce fraud protection for enterprises. Growing but unprofitable, Riskified saw its free cash flow swing positive in the 1Q21.\nFinancial software provider MeridianLink(MLNK) plans to raise $300 million at a $2.1 billion market cap. MeridianLink offers a cloud-based digital lending and account opening platform for mid-market community banks and credit unions. Although business is cyclical, the company saw double-digit organic growth in the FY20 due to strong mortgage activity.\nSmart home integration system Snap One Holdings(SNPO) plans to raise $270 million at a $1.5 billion market cap. This company provides smart home technology products to over 16,000 professional integrators. Snap One has demonstrated solid growth and was profitable on an EBIT basis in the 1Q21.\nSpecialty funding solutions provider Preston Hollow Community Capital(PHCC) plans to raise $200 million at a $2.3 billion market cap. This company is a market leader in providing specialized impact financing solutions for projects of significant social and economic importance to local communities in the US. It serves a variety of areas, including infrastructure, education, healthcare, and housing.\nVaccine biotech Icosavax(ICVX) plans to raise $150 million at a $590 million market cap. This clinical stage biotech is initially focused on developing vaccines against infectious respiratory diseases using its virus-like particle platform technology. Its most advanced candidate is currently in a Phase 1/2 trial for SARS-CoV-2.\nCancer biotech Candel Therapeutics(CADL) plans to raise $85 million at a $398 million market cap. Candel's most advanced candidate is currently in a Phase 3 trial in combination with prodrug valacyclovir for newly diagnosed localized prostate cancer with an intermediate or high-risk for progression. The company expects to complete enrollment in the 3Q21 with a final data readout in 2024.\nRare disease biotech Rallybio(RLYB) plans to raise $81 million at a $465 million market cap. This clinical stage biotech is developing antibody therapies for rare diseases. Its lead program is currently being evaluated to treat fetal and neonatal alloimmune thrombocytopenia in a Phase 1/2 trial.\nOcean Biomedical(OCEA) plans to raise $50 million at a $506 million market cap. The company is currently pursuing preclinical programs in oncology, fibrosis, infectious disease, and inflammation that have been licensed directly or indirectly from Brown University, Stanford University, and Rhode Island Hospital.\nAfter postponing in November 2020,IN8bio(INAB) plans to raise $44 million at a $215 million market cap. This Phase 1 biotech is developing allogeneic gamma-delta T cell therapies to treat solid tumors. Although gamma-delta T cells could potentially treat solid tumors, the company is very early stage and has dosed a limited number of patients.\nFemale cancer biotech Context Therapeutics(CNTX) plans to raise $20 million at a $93 million market cap. Context is developing treatments for female cancers, such as breast, ovarian, and endometrial cancer. The company’s lead candidate is currently in Phase 2 trials for ovarian and endometrial cancer, with preliminary results expected in the 2H21 and the 1H22.\n\nIPO Market Snapshot\nThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/22/2021, the Renaissance IPO Index was down 1.0% year-to-date, while the S&P 500 was up 16.3%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 3.0% year-to-date, while the ACWX was up 8.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include EQT Partners and Smoore International.","news_type":1,"symbols_score_info":{"RSKD":0.9,"DUOL":0.9,"PHCC":0.9,"BTRY":0.9,"DOLE":0.9,"ICVX":0.9,".IXIC":0.9,"PWSC":0.9,"CNTX":0.9,"FEOVF":0.9,"SNPO":0.9,"COOK":0.9,"CADLF":0.9,"INAB":0.9,"MLNK":0.9,"TEAD":0.9,".DJI":0.9,".SPX":0.9,"HOOD":0.9,"RLYB":0.9}},"isVote":1,"tweetType":1,"viewCount":1306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177481454,"gmtCreate":1627257652978,"gmtModify":1631892155864,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Busy week ..looks like volatility will be high","listText":"Busy week ..looks like volatility will be high","text":"Busy week ..looks like volatility will be high","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/177481454","repostId":"1100772026","repostType":4,"isVote":1,"tweetType":1,"viewCount":1128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144136942,"gmtCreate":1626271123686,"gmtModify":1631892155869,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Standby bullets","listText":"Standby bullets","text":"Standby bullets","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/144136942","repostId":"1160878205","repostType":4,"isVote":1,"tweetType":1,"viewCount":1087,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144028758,"gmtCreate":1626255225974,"gmtModify":1633928599020,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Good ..... vested up up up","listText":"Good ..... vested up up up","text":"Good ..... vested up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/144028758","repostId":"1158281742","repostType":4,"repost":{"id":"1158281742","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626249848,"share":"https://www.laohunote.com/m/news/1158281742?lang=zh_CN&edition=full","pubTime":"2021-07-14 16:04","market":"us","language":"en","title":"Apple shares rises nearly 1% in premarket trading.<blockquote>苹果股价在盘前交易中上涨近 1%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1158281742","media":"Tiger Newspress","summary":"Apple shares rises nearly 1% in premarket trading.\nApple Inc. has asked suppliers to build as many a","content":"<p>Apple&nbsp;shares rises nearly&nbsp;1% in premarket&nbsp;trading.</p><p><blockquote>苹果股价在盘前交易中上涨近 1%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/35d519e7b8520bdf005ef08215187349\" tg-width=\"1290\" tg-height=\"619\" referrerpolicy=\"no-referrer\">Apple Inc. has asked suppliers to build as many as 90 million next-generation iPhones this year, a sharp increase from its 2020 iPhone shipments, according to people with knowledge of the matter.</p><p><blockquote>据知情人士透露，苹果公司已要求供应商今年生产多达 9000 万部下一代 iPhone，较 2020 年 iPhone 出货量大幅增长。</blockquote></p><p> The Cupertino, California-based tech giant has maintained a consistent level in recent years of roughly 75 million units for the initial run from a device’s launch through the end of the year. The upgraded forecast for 2021 would suggest the company anticipates its first iPhone launch since the rollout of Covid-19 vaccines will unlock additional demand. The next iPhones will be Apple’s second with 5G, a key enticement pushing users to upgrade.</p><p><blockquote>这家总部位于加利福尼亚州库比蒂诺的科技巨头近年来一直保持着稳定的水平，从设备发布到年底，初始运行的销量约为 7500 万台。2021 年的预测升级表明，该公司预计将推出首款 iPhone，因为 Covid-19 疫苗的推出将释放额外的需求。下一代 iPhone 将是苹果推出的第二款 5G 手机，这是促使用户升级的一个关键诱因。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple shares rises nearly 1% in premarket trading.<blockquote>苹果股价在盘前交易中上涨近 1%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple shares rises nearly 1% in premarket trading.<blockquote>苹果股价在盘前交易中上涨近 1%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-07-14 16:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Apple&nbsp;shares rises nearly&nbsp;1% in premarket&nbsp;trading.</p><p><blockquote>苹果股价在盘前交易中上涨近 1%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/35d519e7b8520bdf005ef08215187349\" tg-width=\"1290\" tg-height=\"619\" referrerpolicy=\"no-referrer\">Apple Inc. has asked suppliers to build as many as 90 million next-generation iPhones this year, a sharp increase from its 2020 iPhone shipments, according to people with knowledge of the matter.</p><p><blockquote>据知情人士透露，苹果公司已要求供应商今年生产多达 9000 万部下一代 iPhone，较 2020 年 iPhone 出货量大幅增长。</blockquote></p><p> The Cupertino, California-based tech giant has maintained a consistent level in recent years of roughly 75 million units for the initial run from a device’s launch through the end of the year. The upgraded forecast for 2021 would suggest the company anticipates its first iPhone launch since the rollout of Covid-19 vaccines will unlock additional demand. The next iPhones will be Apple’s second with 5G, a key enticement pushing users to upgrade.</p><p><blockquote>这家总部位于加利福尼亚州库比蒂诺的科技巨头近年来一直保持着稳定的水平，从设备发布到年底，初始运行的销量约为 7500 万台。2021 年的预测升级表明，该公司预计将推出首款 iPhone，因为 Covid-19 疫苗的推出将释放额外的需求。下一代 iPhone 将是苹果推出的第二款 5G 手机，这是促使用户升级的一个关键诱因。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158281742","content_text":"Apple shares rises nearly 1% in premarket trading.\nApple Inc. has asked suppliers to build as many as 90 million next-generation iPhones this year, a sharp increase from its 2020 iPhone shipments, according to people with knowledge of the matter.\nThe Cupertino, California-based tech giant has maintained a consistent level in recent years of roughly 75 million units for the initial run from a device’s launch through the end of the year. The upgraded forecast for 2021 would suggest the company anticipates its first iPhone launch since the rollout of Covid-19 vaccines will unlock additional demand. The next iPhones will be Apple’s second with 5G, a key enticement pushing users to upgrade.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":895,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145330975,"gmtCreate":1626188995397,"gmtModify":1633929208917,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/145330975","repostId":"1128855782","repostType":4,"isVote":1,"tweetType":1,"viewCount":983,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145395477,"gmtCreate":1626188877299,"gmtModify":1633929210306,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/145395477","repostId":"2151561465","repostType":4,"isVote":1,"tweetType":1,"viewCount":965,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142519241,"gmtCreate":1626160492783,"gmtModify":1631883982784,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"So volatile, bad news and good news one after another","listText":"So volatile, bad news and good news one after another","text":"So volatile, bad news and good news one after another","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/142519241","repostId":"1161696324","repostType":4,"isVote":1,"tweetType":1,"viewCount":1008,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":831038307,"gmtCreate":1629271652709,"gmtModify":1631885409381,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Tepper sell mostly FAANG counter and adding Uber ..... holding cash or&nbsp;expecting buy in dip!","listText":"Tepper sell mostly FAANG counter and adding Uber ..... holding cash or&nbsp;expecting buy in dip!","text":"Tepper sell mostly FAANG counter and adding Uber ..... holding cash or expecting buy in dip!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/831038307","repostId":"1137059057","repostType":4,"isVote":1,"tweetType":1,"viewCount":3918,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807727668,"gmtCreate":1628060748754,"gmtModify":1631892155849,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Vaccine follow by booster.... then booster combine w flu med ...how many vaccine a human need!","listText":"Vaccine follow by booster.... then booster combine w flu med ...how many vaccine a human need!","text":"Vaccine follow by booster.... then booster combine w flu med ...how many vaccine a human need!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807727668","repostId":"1124757232","repostType":4,"repost":{"id":"1124757232","kind":"news","pubTimestamp":1628045612,"share":"https://www.laohunote.com/m/news/1124757232?lang=zh_CN&edition=full","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical 和 Novavax 的股票在 2021 年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul>  <li>Pfizer might surprise to the upside.</li>  <li>Inari Medical is growing like gangbusters.</li>  <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞公司可能会感到惊讶。</li><li>Inari Medical 正在像破坏者一样成长。</li><li>随着 COVID-19 病毒的变异，Novavax 的疫苗可能是一种重要的加强注射。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待着正常化。但COVID正在变异，新德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>一个由 Motley Fool 撰稿人组成的小组为医疗保健股提供了三个想法，即使 COVID 情况变得更糟，这些股票也将在 2021 年上涨。阅读更多内容，了解为什么您可能想要购买股票<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">稻荷医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;-- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更大的运行空间</b></h3><b>乔治·布德威尔</b> <b>（辉瑞）：</b>美国制药巨头辉瑞在目前的新冠疫苗参与者中听起来可能不是一个性感的选择。华尔街目前的共识是制药商的疫苗 Comirnaty——与<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>-- 从 2022 年开始，从销售角度来看，势头将会减弱。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty 的商业寿命可能会比最初预期的长得多。虽然高度传播变种的出现对整个社会来说显然是一个可怕的消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company&nbsp;announced&nbsp;that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因 delta 问题而走高。首先也是最重要的，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。第二，辉瑞计划本月开始针对delta特异性版本的疫苗进行临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品和药物管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞公司已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株病毒的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对投资者来说，大局是辉瑞 2022 年的收入可能比 2021 年增长多达 9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了 delta 特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比 2021 年下降 14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a&nbsp;dividend-paying&nbsp;big pharma stock.</p><p><blockquote>辉瑞的股票可能会走向何方？从保守的角度来看，如果疫苗方面的所有因素都到位，股价应该达到 50 美元。这比该制药商的股价目前上涨了约 17%，这甚至还没有考虑到该公司目前水平下诱人的 3.64% 股息收益率。简而言之，如果这种情况发生，辉瑞的股票交易价格将仅为 2022 年销售额的 3.5 倍左右，这对于支付股息的大型制药股来说是一个相当温和的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b>&nbsp;<b>(Inari Medical):</b>&nbsp;If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to&nbsp;<i>The New York Times</i>&nbsp;-- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>稻荷医疗：销售额飙升</b></h3><b>帕特里克·巴富马</b> <b>（稻荷医疗）：</b>如果您正在寻找一只在疫情的顺风消退后具有持久动力的股票，请关注 Inari Medical。根据数据，2021 年 7 月 27 日新增 108,000 例新冠病例，为 2021 年 2 月 5 日以来最多<i>纽约时报</i>-- 这个数字是 7 月初七天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者致残和潜在威胁生命的血栓风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否可以完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021,&nbsp;up 130% from the same quarter last year&nbsp;and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在去除大血栓，而不需要强效的血栓破除药物。通过使用其ClotTriever和FlowTriever设备，Inari迄今已治疗了超过25,000名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500例手术，比去年同期增长130%，比2020年第四季度高出约20%。根据数据，截至 7 月 27 日，约 12% 的入院 COVID 患者出现血栓，美国约有 35,000 名 COVID 住院病人（并且还在增加）<i>泰晤士报</i>Inari 可能会看到符合条件的案件数量有所增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的成果非常惊人：</blockquote></p><p> <ul>  <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li>  <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li>  <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li>  <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>肺部中高危血栓的历史30天死亡率为9.7%，Inari 0.4%的30天死亡率令人印象深刻。</li><li>与常规护理的24.4%相比，30天再入院率下降了6.7%。</li><li>48小时内发生重大不良事件的发生率仅为1.3%。</li><li>手术后不需要在ICU住院。</li></ul>把所有这些加起来，Inari的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and&nbsp;18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，Inari 的市销率为 18，使其成为待售的成长型股票。</blockquote></p><p> Inari has&nbsp;less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari 在价值 38 亿美元的美国市场的渗透率不到 5%，而且在今年早些时候推出的欧洲也有很大的增长空间。这意味着这家市值 45 亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性手术，但它显然没有减缓Inari的速度，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b>&nbsp;<b>(Novavax):</b>&nbsp;The vaccine&nbsp;biotech&nbsp;Novavax had an amazing 2020, with its share price running up&nbsp;2,700%&nbsp;on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能升到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司 Novavax 在 2020 年表现出色，由于对其 COVID 疫苗的乐观情绪，其股价上涨了 2,700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股上涨了60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19 疫苗的积极第三阶段数据导致该股在年初飙升，但由于该公司将疫苗推向市场出现延误，股价已回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同制造设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管有这些延迟，长期投资者仍有理由看涨。制造业正在扩大规模，预计到第三季度末产量将达到每月 1 亿剂，到 12 月产量将达到每月 1.5 亿剂。虽然美国许多人已经接种了疫苗，但世界其他地区的机会是巨大的。Novavax 已向 COVAX（国际疫苗财团）预售了 11 亿剂疫苗，并已签约在全球供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a&nbsp;booster shot&nbsp;for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told&nbsp;<i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用作已经接种疫苗的人的加强注射。F.D.A. 代理首席科学家卢西亚娜·博里奥 (Luciana Borio) 博士表示：“它们可能确实是加强剂的合适选择。”2015年至2017年，被告知<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax 计划将其 COVID 疫苗与流感疫苗结合起来，形成一次性注射方案。虽然COVID的变异速度不如流感快，但在过去的一年里，我们已经看到了几种变异菌株。在未来几年，我们很可能需要接种不止一次疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-08-04 10:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical 和 Novavax 的股票在 2021 年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul>  <li>Pfizer might surprise to the upside.</li>  <li>Inari Medical is growing like gangbusters.</li>  <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞公司可能会感到惊讶。</li><li>Inari Medical 正在像破坏者一样成长。</li><li>随着 COVID-19 病毒的变异，Novavax 的疫苗可能是一种重要的加强注射。</li></ul>2020年，新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗，并期待着正常化。但COVID正在变异，新德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己？</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>一个由 Motley Fool 撰稿人组成的小组为医疗保健股提供了三个想法，即使 COVID 情况变得更糟，这些股票也将在 2021 年上涨。阅读更多内容，了解为什么您可能想要购买股票<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">稻荷医疗公司。</a></b>，和<b><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;-- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞：更大的运行空间</b></h3><b>乔治·布德威尔</b> <b>（辉瑞）：</b>美国制药巨头辉瑞在目前的新冠疫苗参与者中听起来可能不是一个性感的选择。华尔街目前的共识是制药商的疫苗 Comirnaty——与<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>-- 从 2022 年开始，从销售角度来看，势头将会减弱。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而，由于德尔塔变异毒株，Comirnaty 的商业寿命可能会比最初预期的长得多。虽然高度传播变种的出现对整个社会来说显然是一个可怕的消息，但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company&nbsp;announced&nbsp;that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因 delta 问题而走高。首先也是最重要的，该公司宣布，最早可能在本月提交第三次加强注射的紧急使用授权。第二，辉瑞计划本月开始针对delta特异性版本的疫苗进行临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品和药物管理局和疾病控制与预防中心最近都淡化了加强注射的必要性，但辉瑞公司已经提出了第三次注射的令人信服的理由，以应对德尔塔变异毒株病毒的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对投资者来说，大局是辉瑞 2022 年的收入可能比 2021 年增长多达 9.7%——也就是说，如果加强注射确实获得批准，并且该公司还成功开发了 delta 特异性疫苗。相比之下，华尔街目前预计该制药商明年的营收将比 2021 年下降 14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a&nbsp;dividend-paying&nbsp;big pharma stock.</p><p><blockquote>辉瑞的股票可能会走向何方？从保守的角度来看，如果疫苗方面的所有因素都到位，股价应该达到 50 美元。这比该制药商的股价目前上涨了约 17%，这甚至还没有考虑到该公司目前水平下诱人的 3.64% 股息收益率。简而言之，如果这种情况发生，辉瑞的股票交易价格将仅为 2022 年销售额的 3.5 倍左右，这对于支付股息的大型制药股来说是一个相当温和的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b>&nbsp;<b>(Inari Medical):</b>&nbsp;If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to&nbsp;<i>The New York Times</i>&nbsp;-- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>稻荷医疗：销售额飙升</b></h3><b>帕特里克·巴富马</b> <b>（稻荷医疗）：</b>如果您正在寻找一只在疫情的顺风消退后具有持久动力的股票，请关注 Inari Medical。根据数据，2021 年 7 月 27 日新增 108,000 例新冠病例，为 2021 年 2 月 5 日以来最多<i>纽约时报</i>-- 这个数字是 7 月初七天平均水平的八倍多。更糟糕的是，COVID不仅会导致呼吸困难，还会使患者致残和潜在威胁生命的血栓风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时，接种疫苗是否可以完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021,&nbsp;up 130% from the same quarter last year&nbsp;and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说，这似乎是一个很好的设置，该公司开发了微创产品，旨在去除大血栓，而不需要强效的血栓破除药物。通过使用其ClotTriever和FlowTriever设备，Inari迄今已治疗了超过25,000名患者。2021年第一季度，临床医生使用该公司的设备进行了约5,500例手术，比去年同期增长130%，比2020年第四季度高出约20%。根据数据，截至 7 月 27 日，约 12% 的入院 COVID 患者出现血栓，美国约有 35,000 名 COVID 住院病人（并且还在增加）<i>泰晤士报</i>Inari 可能会看到符合条件的案件数量有所增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的成果非常惊人：</blockquote></p><p> <ul>  <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li>  <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li>  <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li>  <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>肺部中高危血栓的历史30天死亡率为9.7%，Inari 0.4%的30天死亡率令人印象深刻。</li><li>与常规护理的24.4%相比，30天再入院率下降了6.7%。</li><li>48小时内发生重大不良事件的发生率仅为1.3%。</li><li>手术后不需要在ICU住院。</li></ul>把所有这些加起来，Inari的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and&nbsp;18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%，环比增长18%，2021年第一季度毛利率为91.9%。因此，Inari 的市销率为 18，使其成为待售的成长型股票。</blockquote></p><p> Inari has&nbsp;less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari 在价值 38 亿美元的美国市场的渗透率不到 5%，而且在今年早些时候推出的欧洲也有很大的增长空间。这意味着这家市值 45 亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性手术，但它显然没有减缓Inari的速度，甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b>&nbsp;<b>(Novavax):</b>&nbsp;The vaccine&nbsp;biotech&nbsp;Novavax had an amazing 2020, with its share price running up&nbsp;2,700%&nbsp;on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax：能升到多高？</b></h3><b>泰勒·卡迈克尔</b> <b>（诺瓦瓦克斯）：</b>疫苗生物技术公司 Novavax 在 2020 年表现出色，由于对其 COVID 疫苗的乐观情绪，其股价上涨了 2,700%。虽然该公司尚未申请紧急使用授权，但预计将在本季度申请。2021年迄今为止，该股上涨了60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19 疫苗的积极第三阶段数据导致该股在年初飙升，但由于该公司将疫苗推向市场出现延误，股价已回落。首先，制造疫苗所需的原材料短缺。现在，该公司必须证明其各种合同制造设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管有这些延迟，长期投资者仍有理由看涨。制造业正在扩大规模，预计到第三季度末产量将达到每月 1 亿剂，到 12 月产量将达到每月 1.5 亿剂。虽然美国许多人已经接种了疫苗，但世界其他地区的机会是巨大的。Novavax 已向 COVAX（国际疫苗财团）预售了 11 亿剂疫苗，并已签约在全球供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a&nbsp;booster shot&nbsp;for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told&nbsp;<i>The New York Times</i>.</p><p><blockquote>在美国，Novavax疫苗可能主要用作已经接种疫苗的人的加强注射。F.D.A. 代理首席科学家卢西亚娜·博里奥 (Luciana Borio) 博士表示：“它们可能确实是加强剂的合适选择。”2015年至2017年，被告知<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来，Novavax 计划将其 COVID 疫苗与流感疫苗结合起来，形成一次性注射方案。虽然COVID的变异速度不如流感快，但在过去的一年里，我们已经看到了几种变异菌株。在未来几年，我们很可能需要接种不止一次疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"NARI":0.9}},"isVote":1,"tweetType":1,"viewCount":2549,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883740875,"gmtCreate":1631276713897,"gmtModify":1631892155839,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"10 to 15% good for buy the dip","listText":"10 to 15% good for buy the dip","text":"10 to 15% good for buy the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/883740875","repostId":"2166897344","repostType":4,"isVote":1,"tweetType":1,"viewCount":2662,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898668126,"gmtCreate":1628494048065,"gmtModify":1631892155844,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Too big to move exponentially...this will be long term investment","listText":"Too big to move exponentially...this will be long term investment","text":"Too big to move exponentially...this will be long term investment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/898668126","repostId":"2157492988","repostType":4,"isVote":1,"tweetType":1,"viewCount":3213,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808039979,"gmtCreate":1627541757591,"gmtModify":1631892155854,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"With herd immunity and movement allowed, screen time will be reduce..everyone is looking forward to step out","listText":"With herd immunity and movement allowed, screen time will be reduce..everyone is looking forward to step out","text":"With herd immunity and movement allowed, screen time will be reduce..everyone is looking forward to step out","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/808039979","repostId":"2154927641","repostType":4,"isVote":1,"tweetType":1,"viewCount":802,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142519241,"gmtCreate":1626160492783,"gmtModify":1631883982784,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"So volatile, bad news and good news one after another","listText":"So volatile, bad news and good news one after another","text":"So volatile, bad news and good news one after another","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/142519241","repostId":"1161696324","repostType":4,"isVote":1,"tweetType":1,"viewCount":1008,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146382841,"gmtCreate":1626054027883,"gmtModify":1633930617685,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"looking forward&nbsp;","listText":"looking forward&nbsp;","text":"looking forward","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/146382841","repostId":"1114863871","repostType":4,"isVote":1,"tweetType":1,"viewCount":866,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835854435,"gmtCreate":1629706484927,"gmtModify":1631892155842,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"BRK &amp; SE .... the least also 10% return pa ....&nbsp;long term holding&nbsp; ..[美金]&nbsp;[美金]&nbsp;","listText":"BRK &amp; SE .... the least also 10% return pa ....&nbsp;long term holding&nbsp; ..[美金]&nbsp;[美金]&nbsp;","text":"BRK & SE .... the least also 10% return pa .... long term holding ..[美金] [美金]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/835854435","repostId":"2161742695","repostType":4,"isVote":1,"tweetType":1,"viewCount":3861,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":145330975,"gmtCreate":1626188995397,"gmtModify":1633929208917,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/145330975","repostId":"1128855782","repostType":4,"isVote":1,"tweetType":1,"viewCount":983,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":693715823,"gmtCreate":1640079044082,"gmtModify":1640079045141,"author":{"id":"4087387556186030","authorId":"4087387556186030","name":"peng321","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087387556186030","idStr":"4087387556186030"},"themes":[],"title":"","htmlText":"Strongly agree","listText":"Strongly agree","text":"Strongly agree","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693715823","repostId":"1112391676","repostType":4,"repost":{"id":"1112391676","kind":"news","pubTimestamp":1640056217,"share":"https://www.laohunote.com/m/news/1112391676?lang=zh_CN&edition=full","pubTime":"2021-12-21 11:10","market":"us","language":"en","title":"Apple Stock: If You're Buying the Dip, Here's What You Need to Know<blockquote>苹果股票：如果您要逢低买入，以下是您需要了解的内容</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1112391676","media":"TheStreet","summary":"Bargain hunters may start to consider buying Apple stock on the dip, following the December selloff. Here is what they should know first.Apple stock remains in a funk. Only one week to the dayafter I tossed around the ideaof trimming the position, shares of the Cupertino company dipped 7% from the $180 peak against the Nasdaq’s 4% decline, nearly entering correction territory.A few brave investors and traders must be taking this opportunity to start buying the dip. The Apple Maven highlights thr","content":"<p>Bargain hunters may start to consider buying Apple stock on the dip, following the December selloff. Here is what they should know first.</p><p><blockquote>继 12 月抛售之后，逢低买入苹果股票可能会开始考虑逢低买入。以下是他们首先应该知道的。</blockquote></p><p> Apple stock&nbsp;remains in a funk. Only one week to the dayafter I tossed around the ideaof trimming the position, shares of the Cupertino company dipped 7% from the $180 peak against the Nasdaq’s 4% decline, nearly entering correction territory.</p><p><blockquote>苹果股票仍然恐慌。在我抛出削减头寸的想法仅仅一周后，这家库比蒂诺公司的股价从 180 美元的峰值下跌了 7%，而纳斯达克则下跌了 4%，几乎进入了回调区。</blockquote></p><p> A few brave investors and traders must be taking this opportunity to start buying the dip. The Apple Maven highlights three facts that these bargain hunters should keep in mind.</p><p><blockquote>一些勇敢的投资者和交易者一定会抓住这个机会开始逢低买入。这位苹果专家强调了这些抄底者应该记住的三个事实。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a182a349bbd4ca16a13dace221ec341e\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple store in China.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：苹果在华门店。</span></p></blockquote></p><p> <b>#1. Valuations are looking more attractive</b></p><p><blockquote><b>#1.估值看起来更具吸引力</b></blockquote></p><p> AAPL is far from being a dirt cheap stock. The price-to-earnings ratio today is still higher than it had been for at least the full decade prior to the start of the pandemic (see chart below). However, with the recent decline in share price but still resilient business fundamentals, valuations are starting to look more compelling.</p><p><blockquote>AAPL 远非一只非常便宜的股票。如今的市盈率仍然高于疫情爆发前至少整整十年的水平（见下图）。然而，随着最近股价下跌但业务基本面仍然有弹性，估值开始看起来更具吸引力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/75ae50cce66d14520a3db0ce721b79a3\" tg-width=\"827\" tg-height=\"389\" width=\"100%\" height=\"auto\"><span>Figure 2: AAPL's historical price-to-earnings ratio.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图 2：AAPL 的历史市盈率。</span></p></blockquote></p><p> The last read on the graph above shows a P/E of 29.0 times as of November 30. As of last check, on December 20, the fiscal 2022 multiple had dropped to 27.5 times. These are roughly the same levels of June 2020, after which Apple stock moved 85% higher in a year and a half.</p><p><blockquote>上图的最后一次读数显示，截至 11 月 30 日，市盈率为 29.0 倍。截至 12 月 20 日的最后一次检查，2022 财年倍数已降至 27.5 倍。这些水平与 2020 年 6 月大致相同，之后苹果股价在一年半内上涨了 85%。</blockquote></p><p> <b>#2. The deeper the hole, the higher the gains</b></p><p><blockquote><b>#2.洞越深，收益越高</b></blockquote></p><p> “Buy low, sell high”. The mantra may seem overly simplistic, but the strategy has worked wonders in the case of AAPL.</p><p><blockquote>“低买高卖”。这个口头禅可能看起来过于简单，但这个策略在苹果公司的案例中创造了奇迹。</blockquote></p><p> We have often mentioned here, on the Apple Maven channel, that shares of the Cupertino company&nbsp;do best when bought after a selloff. Historically, the one-year gains have been 22% when the stock is bought near a peak, but nearly 40% when bought after a 15% drawdown.</p><p><blockquote>我们经常在苹果 Maven 频道上提到，库比蒂诺公司的股票在抛售后买入时表现最好。从历史上看，当股票在峰值附近买入时，一年涨幅为 22%，但在下跌 15% 后买入时，一年涨幅接近 40%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9439be7d48cbf04254a822d9d57576f3\" tg-width=\"601\" tg-height=\"361\" width=\"100%\" height=\"auto\"><span>Figure 3: Average one-year return on AAPL, by strategy.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图 3：按策略划分的 AAPL 平均一年回报率。</span></p></blockquote></p><p> Could this time be different for dip buyers? I think not. To be clear, I do not believe that every stock is worth owning on weakness, as “40% of all stocks have&nbsp;suffered&nbsp;a permanent 70%-plus decline from their peak value”.</p><p><blockquote>对于逢低买家来说，这次会有所不同吗？我不这么认为。需要明确的是，我并不认为每只股票都值得在疲软时持有，因为 “40% 的股票从峰值永久性下跌了 70% 以上”。</blockquote></p><p> But in the case of Apple, it is highly likely that share price will eventually head higher again, shaking off short-term bearishness and chasing the strong business fundamentals. Having the patience to wait for the next rally is crucial.</p><p><blockquote>但就苹果而言，股价最终极有可能再次走高，摆脱短期看跌情绪，追逐强劲的商业基本面。耐心等待下一次反弹至关重要。</blockquote></p><p> <b>#3. Don’t underestimate volatility</b></p><p><blockquote><b>#3.不要低估波动性</b></blockquote></p><p> All the above sounds bullish at first glance, and an incentive to buy Apple at the current share price of around $168. But if doing so, I urge traders and investors to pay attention to volatility.</p><p><blockquote>乍一看，以上所有情况听起来都很乐观，并且是以目前 168 美元左右的股价购买苹果的动力。但如果这样做，我敦促交易者和投资者关注波动性。</blockquote></p><p> The emotional and psychological aspects of investing can be as important as the quantitative considerations, in my view. Those who buy dips must be willing to endure higher volatility, which has increased sharply for AAPL in the past few weeks — see below.</p><p><blockquote>在我看来，投资的情感和心理方面与数量方面的考虑一样重要。那些逢低买入的人必须愿意忍受更高的波动性，而过去几周 AAPL 的波动性急剧增加——见下文。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eace3c9293acb54a4dc217debd6a44be\" tg-width=\"618\" tg-height=\"370\" width=\"100%\" height=\"auto\"><span>Figure 4: Annual volatility in AAPL, 1-month rolling.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图 4：AAPL 的年度波动性，1 个月滚动。</span></p></blockquote></p><p> Because Apple stock price is likely to ricochet in the short term, some might be tempted to sell their shares prematurely, should they drop well below current levels. If buying AAPL, be sure to have a clear exit strategy to avoid falling victim to spur-of-the-moment decisions.</p><p><blockquote>由于苹果股价可能在短期内反弹，如果股价远低于当前水平，一些人可能会试图过早出售股票。如果购买 AAPL，请务必制定明确的退出策略，以避免成为一时冲动决定的受害者。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: If You're Buying the Dip, Here's What You Need to Know<blockquote>苹果股票：如果您要逢低买入，以下是您需要了解的内容</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: If You're Buying the Dip, Here's What You Need to Know<blockquote>苹果股票：如果您要逢低买入，以下是您需要了解的内容</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-12-21 11:10</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Bargain hunters may start to consider buying Apple stock on the dip, following the December selloff. Here is what they should know first.</p><p><blockquote>继 12 月抛售之后，逢低买入苹果股票可能会开始考虑逢低买入。以下是他们首先应该知道的。</blockquote></p><p> Apple stock&nbsp;remains in a funk. Only one week to the dayafter I tossed around the ideaof trimming the position, shares of the Cupertino company dipped 7% from the $180 peak against the Nasdaq’s 4% decline, nearly entering correction territory.</p><p><blockquote>苹果股票仍然恐慌。在我抛出削减头寸的想法仅仅一周后，这家库比蒂诺公司的股价从 180 美元的峰值下跌了 7%，而纳斯达克则下跌了 4%，几乎进入了回调区。</blockquote></p><p> A few brave investors and traders must be taking this opportunity to start buying the dip. The Apple Maven highlights three facts that these bargain hunters should keep in mind.</p><p><blockquote>一些勇敢的投资者和交易者一定会抓住这个机会开始逢低买入。这位苹果专家强调了这些抄底者应该记住的三个事实。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a182a349bbd4ca16a13dace221ec341e\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple store in China.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：苹果在华门店。</span></p></blockquote></p><p> <b>#1. Valuations are looking more attractive</b></p><p><blockquote><b>#1.估值看起来更具吸引力</b></blockquote></p><p> AAPL is far from being a dirt cheap stock. The price-to-earnings ratio today is still higher than it had been for at least the full decade prior to the start of the pandemic (see chart below). However, with the recent decline in share price but still resilient business fundamentals, valuations are starting to look more compelling.</p><p><blockquote>AAPL 远非一只非常便宜的股票。如今的市盈率仍然高于疫情爆发前至少整整十年的水平（见下图）。然而，随着最近股价下跌但业务基本面仍然有弹性，估值开始看起来更具吸引力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/75ae50cce66d14520a3db0ce721b79a3\" tg-width=\"827\" tg-height=\"389\" width=\"100%\" height=\"auto\"><span>Figure 2: AAPL's historical price-to-earnings ratio.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图 2：AAPL 的历史市盈率。</span></p></blockquote></p><p> The last read on the graph above shows a P/E of 29.0 times as of November 30. As of last check, on December 20, the fiscal 2022 multiple had dropped to 27.5 times. These are roughly the same levels of June 2020, after which Apple stock moved 85% higher in a year and a half.</p><p><blockquote>上图的最后一次读数显示，截至 11 月 30 日，市盈率为 29.0 倍。截至 12 月 20 日的最后一次检查，2022 财年倍数已降至 27.5 倍。这些水平与 2020 年 6 月大致相同，之后苹果股价在一年半内上涨了 85%。</blockquote></p><p> <b>#2. The deeper the hole, the higher the gains</b></p><p><blockquote><b>#2.洞越深，收益越高</b></blockquote></p><p> “Buy low, sell high”. The mantra may seem overly simplistic, but the strategy has worked wonders in the case of AAPL.</p><p><blockquote>“低买高卖”。这个口头禅可能看起来过于简单，但这个策略在苹果公司的案例中创造了奇迹。</blockquote></p><p> We have often mentioned here, on the Apple Maven channel, that shares of the Cupertino company&nbsp;do best when bought after a selloff. Historically, the one-year gains have been 22% when the stock is bought near a peak, but nearly 40% when bought after a 15% drawdown.</p><p><blockquote>我们经常在苹果 Maven 频道上提到，库比蒂诺公司的股票在抛售后买入时表现最好。从历史上看，当股票在峰值附近买入时，一年涨幅为 22%，但在下跌 15% 后买入时，一年涨幅接近 40%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9439be7d48cbf04254a822d9d57576f3\" tg-width=\"601\" tg-height=\"361\" width=\"100%\" height=\"auto\"><span>Figure 3: Average one-year return on AAPL, by strategy.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图 3：按策略划分的 AAPL 平均一年回报率。</span></p></blockquote></p><p> Could this time be different for dip buyers? I think not. To be clear, I do not believe that every stock is worth owning on weakness, as “40% of all stocks have&nbsp;suffered&nbsp;a permanent 70%-plus decline from their peak value”.</p><p><blockquote>对于逢低买家来说，这次会有所不同吗？我不这么认为。需要明确的是，我并不认为每只股票都值得在疲软时持有，因为 “40% 的股票从峰值永久性下跌了 70% 以上”。</blockquote></p><p> But in the case of Apple, it is highly likely that share price will eventually head higher again, shaking off short-term bearishness and chasing the strong business fundamentals. Having the patience to wait for the next rally is crucial.</p><p><blockquote>但就苹果而言，股价最终极有可能再次走高，摆脱短期看跌情绪，追逐强劲的商业基本面。耐心等待下一次反弹至关重要。</blockquote></p><p> <b>#3. Don’t underestimate volatility</b></p><p><blockquote><b>#3.不要低估波动性</b></blockquote></p><p> All the above sounds bullish at first glance, and an incentive to buy Apple at the current share price of around $168. But if doing so, I urge traders and investors to pay attention to volatility.</p><p><blockquote>乍一看，以上所有情况听起来都很乐观，并且是以目前 168 美元左右的股价购买苹果的动力。但如果这样做，我敦促交易者和投资者关注波动性。</blockquote></p><p> The emotional and psychological aspects of investing can be as important as the quantitative considerations, in my view. Those who buy dips must be willing to endure higher volatility, which has increased sharply for AAPL in the past few weeks — see below.</p><p><blockquote>在我看来，投资的情感和心理方面与数量方面的考虑一样重要。那些逢低买入的人必须愿意忍受更高的波动性，而过去几周 AAPL 的波动性急剧增加——见下文。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eace3c9293acb54a4dc217debd6a44be\" tg-width=\"618\" tg-height=\"370\" width=\"100%\" height=\"auto\"><span>Figure 4: Annual volatility in AAPL, 1-month rolling.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图 4：AAPL 的年度波动性，1 个月滚动。</span></p></blockquote></p><p> Because Apple stock price is likely to ricochet in the short term, some might be tempted to sell their shares prematurely, should they drop well below current levels. If buying AAPL, be sure to have a clear exit strategy to avoid falling victim to spur-of-the-moment decisions.</p><p><blockquote>由于苹果股价可能在短期内反弹，如果股价远低于当前水平，一些人可能会试图过早出售股票。如果购买 AAPL，请务必制定明确的退出策略，以避免成为一时冲动决定的受害者。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/apple/stock/apple-stock-3-key-facts-dip-buyers-must-know\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/stock/apple-stock-3-key-facts-dip-buyers-must-know","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112391676","content_text":"Bargain hunters may start to consider buying Apple stock on the dip, following the December selloff. Here is what they should know first.\nApple stock remains in a funk. Only one week to the dayafter I tossed around the ideaof trimming the position, shares of the Cupertino company dipped 7% from the $180 peak against the Nasdaq’s 4% decline, nearly entering correction territory.\nA few brave investors and traders must be taking this opportunity to start buying the dip. The Apple Maven highlights three facts that these bargain hunters should keep in mind.\nFigure 1: Apple store in China.\n#1. Valuations are looking more attractive\nAAPL is far from being a dirt cheap stock. The price-to-earnings ratio today is still higher than it had been for at least the full decade prior to the start of the pandemic (see chart below). However, with the recent decline in share price but still resilient business fundamentals, valuations are starting to look more compelling.\nFigure 2: AAPL's historical price-to-earnings ratio.\nThe last read on the graph above shows a P/E of 29.0 times as of November 30. As of last check, on December 20, the fiscal 2022 multiple had dropped to 27.5 times. These are roughly the same levels of June 2020, after which Apple stock moved 85% higher in a year and a half.\n#2. The deeper the hole, the higher the gains\n“Buy low, sell high”. The mantra may seem overly simplistic, but the strategy has worked wonders in the case of AAPL.\nWe have often mentioned here, on the Apple Maven channel, that shares of the Cupertino company do best when bought after a selloff. Historically, the one-year gains have been 22% when the stock is bought near a peak, but nearly 40% when bought after a 15% drawdown.\nFigure 3: Average one-year return on AAPL, by strategy.\nCould this time be different for dip buyers? I think not. To be clear, I do not believe that every stock is worth owning on weakness, as “40% of all stocks have suffered a permanent 70%-plus decline from their peak value”.\nBut in the case of Apple, it is highly likely that share price will eventually head higher again, shaking off short-term bearishness and chasing the strong business fundamentals. Having the patience to wait for the next rally is crucial.\n#3. Don’t underestimate volatility\nAll the above sounds bullish at first glance, and an incentive to buy Apple at the current share price of around $168. But if doing so, I urge traders and investors to pay attention to volatility.\nThe emotional and psychological aspects of investing can be as important as the quantitative considerations, in my view. Those who buy dips must be willing to endure higher volatility, which has increased sharply for AAPL in the past few weeks — see below.\nFigure 4: Annual volatility in AAPL, 1-month rolling.\nBecause Apple stock price is likely to ricochet in the short term, some might be tempted to sell their shares prematurely, should they drop well below current levels. If buying AAPL, be sure to have a clear exit strategy to avoid falling victim to spur-of-the-moment decisions.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":3622,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}